{"chunk_type":"transcript_chunk","text":"# LM_endo 1\n# USMLE Step 2 Deep Dive: ë‡Œí•˜ìˆ˜ì²´ (Pituitary Gland) ì •ë³µí•˜ê¸° ğŸ§ \n## 1. Introduction: ì„ìƒì  ì‚¬ê³ ë°©ì‹ (Clinical Framework)\nì´ë²ˆ ê°•ì˜ì˜ ëª©í‘œëŠ” ë‹¨ìˆœ ì•”ê¸°ê°€ ì•„ë‹ˆë¼, **USMLE Step 2**ì—ì„œ ìš”êµ¬í•˜ëŠ” ê²¬ê³ í•œ ì •ì‹ ì  í”„ë ˆì„ì›Œí¬(Mental Framework)ë¥¼ êµ¬ì¶•í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì‹œí—˜ì—ì„œëŠ” ë‹¨ìˆœíˆ ì§ˆë³‘ëª…ì„ ë¬»ëŠ” ê²ƒì´ ì•„ë‹ˆë¼, í˜¼ë€ìŠ¤ëŸ¬ìš´ ì¦ìƒ ì„¸íŠ¸ë¥¼ ê°€ì§„ í™˜ìë¥¼ ì œì‹œí•˜ê³  ë‹¤ìŒ ì¤‘ ê°€ì¥ ì ì ˆí•œ ì¡°ì¹˜ëŠ” ë¬´ì—‡ì¸ì§€(Next Best Step)ë¥¼ ë¬»ìŠµë‹ˆë‹¤.\n- **í•µì‹¬ í¬ì¸íŠ¸:** í˜¸ë¥´ëª¬ ê³¼ë‹¤(Excess) vs ê²°í•(Deficiency) êµ¬ë³„\n- **ì£¼ì˜ ì‚¬í•­:** ì§„ë‹¨ ê²€ì‚¬ì˜ ì •í™•í•œ ìˆœì„œë¥¼ ì§€í‚¤ëŠ” ê²ƒì´ ì ìˆ˜ë¥¼ ì–»ëŠ” í•µì‹¬ì…ë‹ˆë‹¤. (MRIë¥¼ ë„ˆë¬´ ì¼ì° ì°ê±°ë‚˜, í™˜ìë¥¼ ë³´ì§€ ì•Šê³  ìˆ˜ì¹˜ë§Œ ì¹˜ë£Œí•˜ëŠ” í•¨ì •ì„ í”¼í•´ì•¼ í•¨)\n---\n## 2. Hyperpituitarism (ë‡Œí•˜ìˆ˜ì²´ ê¸°ëŠ¥ í•­ì§„ì¦) - Part 1: Prolactinoma ğŸ¥›\nê°€ì¥ í”í•œ ë‡Œí•˜ìˆ˜ì²´ ì¢…ì–‘ì…ë‹ˆë‹¤. í™˜ìì˜ ì„±ë³„ê³¼ ìƒíƒœì— ë”°ë¼ ì„ìƒ ì–‘ìƒì´ ì™„ì „íˆ ë‹¤ë¦…ë‹ˆë‹¤.\n### ğŸš© ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤ (Clinical Presentation)\n| í™˜ìêµ° | ì¦ìƒ (Symptoms) | ê¸°ì „ (Mechanism) |\n| --- | --- | --- |\n| **íê²½ ì „ ì—¬ì„±** (Premenopausal Women) | â€¢ **ìƒë¦¬ ë¶ˆìˆœ (Oligomenorrhea/Amenorrhea)**  â€¢ **ë¶ˆì„ (Infertility)**  â€¢ ìœ ì¦™ ë¶„ë¹„ (Galactorrhea)  â€¢ â˜… **ê³¨ë°€ë„ ê°ì†Œ** | ë†’ì€ Prolactinì´ **GnRHë¥¼ ì–µì œ**í•˜ì—¬ Hypogonadism ìœ ë°œ (ì—ìŠ¤íŠ¸ë¡œê² ê°ì†Œë¡œ ì¡°ê¸° íê²½ê³¼ ìœ ì‚¬í•œ ë¼ˆ ì†ì‹¤ ë°œìƒ) |\n| **íê²½ í›„ ì—¬ì„± & ë‚¨ì„±** (Postmenopausal / Men) | â€¢ **ì‹œì•¼ ê²°ì† (Visual Field Defect)**: â˜… **Bitemporal Hemianopsia (í„°ë„ ì‹œì•¼)**  â€¢ ë‘í†µ (Headache)  â€¢ ì„±ìš• ê°í‡´, ë°œê¸° ë¶€ì „ | ìƒë¦¬ë¼ëŠ” 'ì•ŒëŒ'ì´ ì—†ì–´ì„œ ì¢…ì–‘ì´ **Macroadenoma**ê¹Œì§€ ì»¤ì§„ í›„ ë°œê²¬ë¨. **Mass effect**ë¡œ ì‹œì‹ ê²½ êµì°¨(Optic chiasm)ë¥¼ ì••ë°•. |\n### ğŸ§ª ì§„ë‹¨ (Diagnosis): í•¨ì • í”¼í•˜ê¸°\nMRIë¥¼ ì°ê¸° ì „ì— ë°˜ë“œì‹œ í™•ì¸í•´ì•¼ í•  ìˆ˜ì¹˜ë“¤ì´ ìˆìŠµë‹ˆë‹¤.\n1. **Serum Prolactin > 200 ng/mL:** ê±°ì˜ í™•ì •ì (Virtually diagnostic)ì¸ Prolactinoma.\n2. **Gray Zone (20~200 ng/mL):** ì§„ë‹¨ì  ì˜¤ë¥˜ê°€ ë°œìƒí•˜ê¸° ì‰¬ìš´ ìœ„í—˜ êµ¬ì—­. ë°˜ë“œì‹œ ë‹¤ìŒì„ ê°ë³„í•´ì•¼ í•¨.\n### âš ï¸ í•„ìˆ˜ ê°ë³„ ì§ˆí™˜ ë° ìƒí™© (Rule outs)\nMRI ì´¬ì˜ ì „ ë°˜ë“œì‹œ ì²´í¬í•´ì•¼ í•  ë¦¬ìŠ¤íŠ¸:\n- **ì•½ë¬¼ (Medications):** í•­ì •ì‹ ë³‘ ì•½ë¬¼(Haloperidol, Risperidone ë“±) â†’ ë„íŒŒë¯¼(Prolactinì˜ ë¸Œë ˆì´í¬)ì„ ì°¨ë‹¨í•˜ì—¬ ìˆ˜ì¹˜ ìƒìŠ¹.\n- **ìƒë¦¬ì  ìš”ì¸:** ì„ì‹ , ìœ ë‘ ìê·¹, ìŠ¤íŠ¸ë ˆìŠ¤.\n- **â˜… ê°‘ìƒì„  ê¸°ëŠ¥ ì €í•˜ì¦ (Hypothyroidism):**\n    - **ê¸°ì „:** ë‚®ì€ T4 â†’ ì‹œìƒí•˜ë¶€ì—ì„œ TRH ì¦ê°€ â†’ TRHê°€ TSHë¿ë§Œ ì•„ë‹ˆë¼ **Prolactin ë¶„ë¹„ë„ ìê·¹**.\n    - **ì£¼ì˜:** ê°‘ìƒì„  ì €í•˜ì¦ í™˜ìë¥¼ Prolactinomaë¡œ ì˜¤ì¸í•˜ì—¬ ìˆ˜ìˆ í•˜ëŠ” ê²ƒì€ **ì‹¬ê°í•œ ì‹¤ìˆ˜(Massive Mistake)**.\n    - **Next Step:** TSH, Creatinine(ì‹ ë¶€ì „ ë°°ì œ), ì„ì‹  í…ŒìŠ¤íŠ¸ í™•ì¸ í›„ MRI ì´¬ì˜.\n### ğŸ’Š ì¹˜ë£Œ (Management)","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-1","focus_area":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"ProlactinomaëŠ” ë…íŠ¹í•˜ê²Œë„ **ì•½ë¬¼ ì¹˜ë£Œê°€ 1ì°¨ ì¹˜ë£Œ(First-line)**ì…ë‹ˆë‹¤.\n- **1st Line:** **Dopamine Agonists** (ë„íŒŒë¯¼ì€ Prolactinì˜ ë¸Œë ˆì´í¬ ì—­í• )\n    - **Cabergoline** (ì„ í˜¸ë¨: ë¶€ì‘ìš© ì ê³  íš¨ê³¼ ì¢‹ìŒ)\n    - Bromocriptine\n    - íš¨ê³¼: ì¢…ì–‘ í¬ê¸°ë¥¼ ì¤„ì´ê³  Prolactin ìˆ˜ì¹˜ë¥¼ ì •ìƒí™”í•¨.\n- **ìˆ˜ìˆ  (Transsphenoidal Surgery):** ì•½ë¬¼ ì¹˜ë£Œì— ì‹¤íŒ¨í•˜ê±°ë‚˜, ì‹œì•¼ ê²°ì†ì´ ê¸‰ê²©íˆ ì§„í–‰ë˜ì–´ ì•½ë¬¼ ë°˜ì‘ì„ ê¸°ë‹¤ë¦´ ìˆ˜ ì—†ì„ ë•Œë§Œ ì‹œí–‰.\n---\n## 3. Hyperpituitarism - Part 2: Acromegaly (ë§ë‹¨ë¹„ëŒ€ì¦) ğŸ¦\nì„±ì¥ í˜¸ë¥´ëª¬(GH) ê³¼ë‹¤ ë¶„ë¹„ ì§ˆí™˜ì…ë‹ˆë‹¤.\n### ğŸš© ì¦ìƒ ë° ìœ„í—˜ì„±\n- **ì™¸í˜•:** ì´ë§ˆ íŠ€ì–´ë‚˜ì˜´(Frontal bossing), ë¶€ì •êµí•©, **ì»¤ì§„ ì†ê³¼ ë°œ(ë°˜ì§€ë‚˜ ì‹ ë°œ ì‚¬ì´ì¦ˆ ë³€í™”)**.\n- **â˜… So What? (ì™œ ìœ„í—˜í•œê°€):** ë‚´ì¥ ê¸°ê´€ë„ ê°™ì´ ì»¤ì§(Visceral enlargement).\n    - **ì‹¬í˜ˆê´€(CV):** **ì‹¬ë¶€ì „(Heart Failure)**, ì‹¬ê·¼ë³‘ì¦, ê³ í˜ˆì••. â†’ **ê°€ì¥ í”í•œ ì‚¬ë§ ì›ì¸**.\n    - **í˜¸í¡ê¸°:** ìˆ˜ë©´ ë¬´í˜¸í¡ì¦ (ê¸°ë„ ì—°ì¡°ì§ ë¹„ëŒ€).\n    - **ëŒ€ì‚¬:** ë‹¹ë‡¨ë³‘ (GHëŠ” ì¸ìŠë¦° ì €í•­ì„±ì„ ìœ ë°œ).\n    - **â˜… ìœ„ì¥ê´€ê³„:** **ëŒ€ì¥ì•”(Colon Cancer)** ë° ìš©ì¢… ìœ„í—˜ ì¦ê°€.\n        - **High Yield:** Acromegaly ì§„ë‹¨ ì‹œ **ëŒ€ì¥ë‚´ì‹œê²½(Colonoscopy)** ìŠ¤í¬ë¦¬ë‹ì´ í•„ìˆ˜.\n### ğŸ§ª ì§„ë‹¨ í”„ë¡œì„¸ìŠ¤ (2-Step Process)\nì„±ì¥ í˜¸ë¥´ëª¬ì€ í•˜ë£¨ ì¢…ì¼ í„ìŠ¤(pulse) í˜•íƒœë¡œ ë¶„ë¹„ë˜ë¯€ë¡œ ëœë¤ ìˆ˜ì¹˜ëŠ” ë¬´ì˜ë¯¸í•©ë‹ˆë‹¤.\n1. **ìŠ¤í¬ë¦¬ë‹ (Screening):** **IGF-1 (Insulin-like Growth Factor 1)** ì¸¡ì •. (GHì˜ í‰ê· ì¹˜ë¥¼ ë°˜ì˜í•˜ëŠ” ì•ˆì •ì ì¸ ì§€í‘œ)\n2. **í™•ì§„ (Confirmatory):** **ê²½êµ¬ ë‹¹ë¶€í•˜ ê²€ì‚¬ (Oral Glucose Suppression Test)**.\n    - ì •ìƒ: í¬ë„ë‹¹ íˆ¬ì—¬ ì‹œ GH ê°ì†Œ.\n    - Acromegaly: GHê°€ ì–µì œë˜ì§€ ì•Šê³  ë†’ê²Œ ìœ ì§€ë¨.\n3. **MRI:** í™•ì§„ í›„ì—ë§Œ ì‹œí–‰.\n### ğŸ”ª ì¹˜ë£Œ (Management)\n- **1st Line:** **ìˆ˜ìˆ  (Transsphenoidal Resection)**. (Prolactinomaì™€ ë°˜ëŒ€!)\n- **ì•½ë¬¼:** ìˆ˜ìˆ  ì‹¤íŒ¨ ì‹œ Octreotide ë“± ì‚¬ìš©.\n---\n## 4. Posterior Pituitary (í›„ì—½) - ìˆ˜ë¶„ ê· í˜• ğŸ’§\n### ğŸ…°ï¸ SIADH (ë¶€ì ì ˆ í•­ì´ë‡¨í˜¸ë¥´ëª¬ ë¶„ë¹„ ì¦í›„êµ°)\nëª¸ì´ ë¬¼ì„ ë¶€ì ì ˆí•˜ê²Œ ë§ì´ ì¬í¡ìˆ˜í•˜ì—¬ í¬ì„ë˜ëŠ” ìƒíƒœ.\n- **í™˜ì ìƒíƒœ:** **Euvolemic** (ë¶€ì¢… ì—†ìŒ, íƒˆìˆ˜ ì•„ë‹˜ - ì ë§‰ ì´‰ì´‰í•¨).\n- **ì¦ìƒ:** ì €ë‚˜íŠ¸ë¥¨í˜ˆì¦(Hyponatremia) ì†ë„ì— ë”°ë¦„ (ì˜¤ì‹¬, í˜¼ë€, ë°œì‘, í˜¼ìˆ˜).\n- **ì›ì¸ (3ëŒ€ ì¹´í…Œê³ ë¦¬):**\n    1. **CNS:** ë‡Œì¡¸ì¤‘, ì™¸ìƒ, ìˆ˜ë§‰ì—¼ ë“±.\n    2. **Lungs:** íë ´, â˜… **ì†Œì„¸í¬ íì•” (Small Cell Lung Cancer)** - ì´ì†Œì„±(Ectopic) ADH ë¶„ë¹„. (í¡ì—°ìì˜ SIADH = í‰ë¶€ CT í•„ìˆ˜)\n    3. **ì•½ë¬¼:** **SSRIs**, Carbamazepine, NSAIDs.\n- **Labs:**\n    - Serum Osmolality: **Low (< 275)** - í˜ˆì•¡ì€ ë¬½ì–´ì§.\n    - Urine Osmolality: **High (> 100)** - ì†Œë³€ì€ ë†ì¶•ë¨.\n    - Urine Na: **High (> 40)** - ì‹ ì¥ì´ ë¬¼ì„ ì¡ê³  ì†Œê¸ˆì€ ë°°ì„¤.\n- **ì¹˜ë£Œ:**\n    - ê²½ì¦: ìˆ˜ë¶„ ì œí•œ (Fluid restriction).\n    - ì¤‘ì¦(ë°œì‘ ë“±): 3% Hypertonic Saline.\n    - â˜… **ì£¼ì˜:** ë‚˜íŠ¸ë¥¨ì„ ë„ˆë¬´ ë¹¨ë¦¬ êµì •í•˜ë©´ **Osmotic Demyelination Syndrome (Locked-in Syndrome)** ë°œìƒ ìœ„í—˜. \"Correct slowly and carefully.\"\n### ğŸ…±ï¸ Diabetes Insipidus (DI) vs. Primary Polydipsia\nì†Œë³€ëŸ‰ì´ í•˜ë£¨ 3L ì´ìƒì¸ ë‹¤ë‡¨(Polyuria) í™˜ì ê°ë³„.\n- **Water Diuresis (ë¬¼ ì„¤ì‚¬) í™•ì¸:** ë¬½ì€ ì†Œë³€(Dilute urine)ì¸ì§€ í™•ì¸.\n- **â˜… ê°ë³„ í¬ì¸íŠ¸: í˜ˆì¤‘ ë‚˜íŠ¸ë¥¨ (Serum Sodium)**\n    - **Diabetes Insipidus (ìš”ë¶•ì¦):** ë¬¼ì„ ìƒì–´ë²„ë¦¼ â†’ í˜ˆì•¡ ë†ì¶• â†’ **High Sodium (Hypernatremia)**.\n    - **Primary Polydipsia (ë¬¼ ì¤‘ë…):** ë¬¼ì„ ë„ˆë¬´ ë§ì´ ë§ˆì‹¬ â†’ í˜ˆì•¡ í¬ì„ â†’ **Low Sodium (Hyponatremia)**.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-21","focus_area":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","tags":["usmle-step2","core","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"---\n## 5. Hypopituitarism (ë‡Œí•˜ìˆ˜ì²´ ê¸°ëŠ¥ ì €í•˜ì¦) ğŸ“‰\n### ğŸš© ì›ì¸ ë° íŒ¨í„´\n- **ì›ì¸:** ê±°ëŒ€ ì„ ì¢…ì˜ ì••ë°•, ë‡Œí•˜ìˆ˜ì²´ ì¡¸ì¤‘(Apoplexy), ì‰¬í•œ ì¦í›„êµ°(Sheehan's syndrome - ë¶„ë§Œ í›„ ì¶œí˜ˆ), ì¹¨ìœ¤ì„± ì§ˆí™˜(í˜ˆìƒ‰ì†Œì¹¨ì°©ì¦ ë“±).\n- **í˜¸ë¥´ëª¬ ì†Œì‹¤ ìˆœì„œ:** GH/Gonadotropins(FSH/LH) â†’ TSH â†’ ACTH ìˆœìœ¼ë¡œ ì‚¬ë¼ì§.\n### â˜… Primary vs. Secondary Adrenal Insufficiency (ë¶€ì‹  ë¶€ì „) êµ¬ë³„\nStep 2ì—ì„œ ê°€ì¥ ì¤‘ìš”í•œ ê³ ë‚œì´ë„ ê°œë…ì…ë‹ˆë‹¤. ë‘˜ ë‹¤ Cortisolì€ ë‚®ì§€ë§Œ ê²°ì •ì ì¸ ì°¨ì´ê°€ ìˆìŠµë‹ˆë‹¤.\n| íŠ¹ì§• | Primary (Addison's Disease) | Secondary (Pituitary Failure) |\n| --- | --- | --- |\n| **ë³‘ë³€ ìœ„ì¹˜** | ë¶€ì‹  (Adrenal Gland) íŒŒê´´ | ë‡Œí•˜ìˆ˜ì²´ (Pituitary) ACTH ë¶€ì¡± |\n| **Aldosterone** | **ê°ì†Œ** (ë¶€ì‹  ì „ì²´ê°€ íŒŒê´´ë¨) | **ì •ìƒ** (RAAS ì‹œìŠ¤í…œì— ì˜í•´ ì¡°ì ˆë˜ë¯€ë¡œ ACTH ë¬´ê´€) |\n| **Potassium** | **Hyperkalemia** (Aldo ë¶€ì¡±ìœ¼ë¡œ K+ ë°°ì„¤ ëª»í•¨) | **Normal** |\n| **í”¼ë¶€ (Skin)** | â˜… **Hyperpigmentation** (High ACTH â†’ MSH ìê·¹) | **Pale / Alabaster** (ì°½ë°±í•¨, MSH ìê·¹ ì—†ìŒ) |\n| **Salt Craving** | ìˆìŒ | ì—†ìŒ |\n- **ì§„ë‹¨ íŒ:** ì €í˜ˆì•• í™˜ìì—ì„œ **ì €í˜ˆë‹¹(Hypoglycemia)** + **í˜¸ì‚°êµ¬ ì¦ê°€ì¦(Eosinophilia)**ì´ ë³´ì´ë©´, ì„¤ëª…ë˜ì§€ ì•ŠëŠ” í”¼ë¡œì™€ í•¨ê»˜ **Morning Cortisol**ì„ ë°˜ë“œì‹œ ì²´í¬í•´ì•¼ í•©ë‹ˆë‹¤. (Cortisolì´ ë‚®ìœ¼ë©´ í˜¸ì‚°êµ¬ê°€ ì¡°ì§ìœ¼ë¡œ ì´ë™í•˜ì§€ ëª»í•˜ê³  í˜ˆì•¡ì— ë¨¸ë¬¾).\n---\n## ğŸï¸ Rapid Fire Recap (í•µì‹¬ ìš”ì•½) ğŸ”¥\n1. **Prolactinoma:** Serum Prolactin **> 200**. ê°‘ìƒì„ ê¸°ëŠ¥ì €í•˜ì¦(Hypothyroid) ë°°ì œ. ì¹˜ë£ŒëŠ” **Cabergoline** (ì•½ë¬¼) ë¨¼ì €.\n2. **Acromegaly:** í° ì†/í„±, ì‹¬ì¥ ë¬¸ì œ(Bad heart). ìŠ¤í¬ë¦¬ë‹ì€ **IGF-1**, í™•ì§„ì€ **Oral Glucose Suppression**. ì¹˜ë£ŒëŠ” **ìˆ˜ìˆ ** ë¨¼ì €. **ëŒ€ì¥ë‚´ì‹œê²½** í•„ìˆ˜.\n3. **SIADH:** Hyponatremia + Euvolemia + ì§„í•œ ì†Œë³€. **Small Cell Lung Cancer** (í¡ì—°ì)ì™€ SSRI ì²´í¬. ìˆ˜ë¶„ ì œí•œì´ 1ì°¨ ì¹˜ë£Œ.\n4. **DI vs Polydipsia:** í˜ˆì¤‘ ë‚˜íŠ¸ë¥¨(Serum Sodium)ì„ ë³´ë¼. High Na = **Central DI**, Low Na = **Primary Polydipsia**.\n5. **Hypopituitarism vs Primary Adrenal Insufficiency:** ë‡Œí•˜ìˆ˜ì²´ ë¬¸ì œ(Secondary)ëŠ” **Aldosterone ì •ìƒ, Potassium ì •ìƒ, í”¼ë¶€ ì°½ë°±(Pale)**.\n---\n## 6. Closing Thought: Incidentaloma (ìš°ì—°ì¢…)\nCT/MRIì—ì„œ ìš°ì—°íˆ ë°œê²¬ëœ ë‡Œí•˜ìˆ˜ì²´ ì¢…ê´´(Mass)ê°€ ìˆë‹¤ í•´ë„, í˜¸ë¥´ëª¬ ìˆ˜ì¹˜ê°€ ì •ìƒì´ë©´ **í•¨ë¶€ë¡œ ì¹˜ë£Œí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.**\n- í•´ë¶€í•™(Anatomy)ì´ í•­ìƒ ìƒë¦¬í•™(Physiology)ê³¼ ì¼ì¹˜í•˜ëŠ” ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤.\n- ë°˜ë“œì‹œ ìƒí™”í•™ì  ì¦ê±°(Biochemical proof)ë¥¼ í™•ì¸í•˜ê³  ì¹˜ë£Œë¥¼ ê²°ì •í•˜ì‹­ì‹œì˜¤. **\"Trust but verify.\"**\n---\n# ğŸ¦´ USMLE Step 2 Deep Dive: Parathyroid Disorders\nì´ë²ˆ ì„¸ì…˜ì€ ë‹¨ìˆœ ì•”ê¸°(Rote memorization)ë¥¼ ë„˜ì–´, ì‹œí—˜ ë‹¹ì¼ ì‹¤ì œë¡œ í™œìš©í•  ìˆ˜ ìˆëŠ” **ë…¼ë¦¬ì  ì‚¬ê³ (Mental Map)**ë¥¼ êµ¬ì¶•í•˜ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•©ë‹ˆë‹¤. \"Bones, Stones, and Groans\"ë¼ëŠ” ê³ ì „ì ì¸ ì•”ê¸°ë²•ì„ ë„˜ì–´ì„œëŠ” êµ¬ì²´ì ì¸ ìˆ˜ìˆ  ì ì‘ì¦ê³¼ ê¹Œë‹¤ë¡œìš´ ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤ë¥¼ ë‹¤ë£¹ë‹ˆë‹¤.\n## 1. Introduction: The Approach","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-41","focus_area":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","tags":["usmle-step2","core","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"- **ëª©í‘œ:** ë‹¨ìˆœ ë¦¬ìŠ¤íŠ¸ ì•”ê¸°ê°€ ì•„ë‹Œ ìƒë¦¬í•™ì  ë…¼ë¦¬ ì´í•´.\n- **ì´ˆì :** ë¶€ê°‘ìƒì„ (Parathyroid gland), íŠ¹íˆ ê³ ì¹¼ìŠ˜í˜ˆì¦(Hypercalcemia), ìœ ì „ì  ë³€ì´, ìˆ˜ìˆ  ê°€ì´ë“œë¼ì¸, ê·¸ë¦¬ê³  ì‹ ë¶€ì „/ì‹ ìƒì•„ ê´€ë ¨ ì„ìƒ ë¹„ë„¤íŠ¸(Vignette).\n---\n## 2. Primary Hyperparathyroidism (ì›ë°œì„± ë¶€ê°‘ìƒì„  í•­ì§„ì¦)\n### ğŸ©º ë³‘ì¸ (Etiology)\n- **ê°€ì¥ í”í•œ ì›ì¸:** **Parathyroid Adenoma (ë‹¨ì¼ ì„ ì¢…)**ê°€ ì•½ **80~85%** ì°¨ì§€.\n- **ìœ ì „ì  ì—°ê´€ì„±:** ì Šì€ í™˜ìë‚˜ ê°€ì¡±ë ¥ì´ ìˆëŠ” ê²½ìš° **MEN Syndrome**ì„ ì˜ì‹¬í•´ì•¼ í•¨.\n    - MEN Type 1\n    - MEN Type 2A\n    - ì£¼ë¡œ ë‹¤ë°œì„± ì„  ì¦ì‹(Hyperplasia)ê³¼ ê´€ë ¨ë¨.\n### ğŸ¤’ ì„ìƒ ì–‘ìƒ (Presentation)\n- **Textbook:** Bones, Stones, Abdominal Groans, Psychiatric Overtones.\n- **Real World & Exam Trend:** â˜… **ë¬´ì¦ìƒ(Asymptomatic)**ì´ ê°€ì¥ í”í•¨.\n    - ìš°ì—°íˆ ì‹œí–‰í•œ í˜ˆì•¡ ê²€ì‚¬ì—ì„œ ì¹¼ìŠ˜ ìˆ˜ì¹˜ê°€ ë†’ê²Œ ë‚˜ì˜¤ëŠ” ê²½ìš°ê°€ ì „í˜•ì ì¸ ì‹œë‚˜ë¦¬ì˜¤.\n- **ì¦ìƒì´ ìˆëŠ” ê²½ìš°:**\n    - **Renal:** ì‹ ì¥ ê²°ì„ (Calcium Oxalate).\n    - **Bone:** ë¼ˆ í†µì¦ (Resorption).\n    - **Abdominal:** ë³€ë¹„(Constipation), ì˜¤ì‹¬, ì†Œí™”ì„± ê¶¤ì–‘.\n    - **Psych:** í”¼ë¡œê°(Fatigue), ë¸Œë ˆì¸ í¬ê·¸(Brain fog), ì‹¬í•˜ë©´ ìš°ìš¸ì¦/í˜¼ë€.\n### ğŸ©¸ ì§„ë‹¨ì  ê²€ì‚¬ ê²°ê³¼ (Lab Profile)\nì§„ë‹¨ì˜ í•µì‹¬ì€ **ìˆ˜ì¹˜ í•˜ë‚˜ê°€ ì•„ë‹ˆë¼ \"ì¡°í•©(Combination)\"**ì„ ë³´ëŠ” ê²ƒì…ë‹ˆë‹¤.\n| í•­ëª© | ê²°ê³¼ | ì˜ë¯¸ |\n| --- | --- | --- |\n| **Serum Calcium** | **High** | ê³ ì¹¼ìŠ˜í˜ˆì¦ |\n| **PTH** | **High** OR **Inappropriately Normal** | â˜… ì¹¼ìŠ˜ì´ ë†’ì€ë° PTHê°€ ì •ìƒì´ë©´ ë¹„ì •ìƒì„. |\nì¹¼ìŠ˜ì´ ë†’ìœ¼ë©´ ì •ìƒì ì¸ í”¼ë“œë°± ë£¨í”„ì— ì˜í•´ PTHëŠ” ì–µì œë˜ì–´ ë‚®ì•„ì•¼ í•¨. ë§Œì•½ ì¹¼ìŠ˜ì´ ë†’ì€ë° PTHê°€ ì •ìƒ ë²”ìœ„(ì¤‘ê°„ê°’ ë“±)ë¼ë©´, ë¶€ê°‘ìƒì„ ì´ ììœ¨ì ìœ¼ë¡œ ì‘ë™í•˜ê³  ìˆë‹¤ëŠ” ëœ»ì´ë¯€ë¡œ Primary Hyperparathyroidismìœ¼ë¡œ ì§„ë‹¨í•¨.\n## 3. The Imposter: Familial Hypocalciuric Hypercalcemia (FHH)\nê²€ì‚¬ ê²°ê³¼ê°€ Primary Hyperparathyroidismê³¼ ê±°ì˜ ë™ì¼(High Calcium, High/Normal PTH)í•˜ì—¬ \"ìœ„ëŒ€í•œ ëª¨ë°©ê¾¼(The Great Mimic)\"ì´ë¼ ë¶ˆë¦½ë‹ˆë‹¤.\n### ğŸ§¬ ê¸°ì „ ë° íŠ¹ì§•\n- **ì›ì¸:** ì¹¼ìŠ˜ ê°ì§€ ìˆ˜ìš©ì²´(Calcium-sensing receptors)ì˜ ìœ ì „ì  ê²°í•¨.\n- **Set Point:** ì‹ ì¥ê³¼ ë¶€ê°‘ìƒì„ ì˜ ì¹¼ìŠ˜ ì„¸íŠ¸ í¬ì¸íŠ¸ê°€ ë†’ê²Œ ì„¤ì •ë¨.\n- **ì‹ ì¥:** ì¹¼ìŠ˜ì„ ë°°ì¶œí•˜ì§€ ì•Šê³  ê³µê²©ì ìœ¼ë¡œ ì¬í¡ìˆ˜í•¨.\n- **ì¹˜ë£Œ:** **ìˆ˜ìˆ  ê¸ˆì§€ (Contraindicated).** ì–‘ì„± ì§ˆí™˜ì´ë¯€ë¡œ ìˆ˜ìˆ í•´ë„ ì´ë“ì´ ì—†ê³  ìœ„í—˜ë§Œ ë”°ë¦„.\n### âš–ï¸ ê°ë³„ ì§„ë‹¨ (The Tie-Breaker)\n**24-hour Urinary Calcium Excretion Test**ê°€ í•„ìˆ˜ì ì…ë‹ˆë‹¤.\n- **FHH:** ì†Œë³€ ì¹¼ìŠ˜ **ë§¤ìš° ë‚®ìŒ**. (Calcium/Creatinine clearance ratio < **0.01**)\n- **Primary Hyperparathyroidism:** ì†Œë³€ ì¹¼ìŠ˜ **ë†’ìŒ**. (Bodyê°€ ì¹¼ìŠ˜ì„ ê°ë‹¹ ëª»í•´ ì†Œë³€ìœ¼ë¡œ ë„˜ì¹¨, Ratio > **0.02**)\n- **ì„ìƒì  ì¡°ì–¸:** ìˆ˜ìˆ  ì „ ë°˜ë“œì‹œ ì†Œë³€ ê²€ì‚¬ë¥¼ í†µí•´ FHHë¥¼ ë°°ì œí•´ì•¼ í•¨ (Medical Malpractice ë°©ì§€).\n---","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-61","focus_area":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","tags":["usmle-step2","core"]}
{"chunk_type":"transcript_chunk","text":"## 4. ğŸ‘¶ Clinical Vignette: The Neonatal Crash\n**ì‹œë‚˜ë¦¬ì˜¤:** ê±´ê°•í•´ ë³´ì´ëŠ” ì‹ ìƒì•„(ë‚¨ì•„)ê°€ ìƒí›„ 3ì¼ì§¸ ê²½ë ¨(Seizure), ë¹ˆí˜¸í¡, ê·¼ìœ¡ ì—°ì¶•(Spasm)ìœ¼ë¡œ ë‚´ì›.\n- **ì•„ê¸° Labs:** **Hypocalcemia (ì €ì¹¼ìŠ˜í˜ˆì¦)** + **Low PTH**.\n- **ì›ì¸:** **ì—„ë§ˆì˜ ì§„ë‹¨ë˜ì§€ ì•Šì€ FHH (Maternal FHH).**\n### ğŸ”„ ë°œìƒ ê¸°ì „\n1. **ì„ì‹  ì¤‘:** ì—„ë§ˆ(FHH)ì˜ ë†’ì€ ì¹¼ìŠ˜ì´ íƒœë°˜ì„ í†µê³¼ â†’ íƒœì•„ëŠ” ê³ ì¹¼ìŠ˜ í™˜ê²½ì— ë…¸ì¶œ.\n2. **íƒœì•„ ë°˜ì‘:** íƒœì•„ì˜ ë¶€ê°‘ìƒì„ ì€ \"ì¹¼ìŠ˜ì´ ë„ˆë¬´ ë§ë‹¤\"ê³  íŒë‹¨í•˜ì—¬ **ê¸°ëŠ¥ì´ ì–µì œë¨(Sleep mode).**\n3. **ì¶œìƒ í›„:** íƒ¯ì¤„ì´ ëŠì–´ì§€ë©° ì—„ë§ˆë¡œë¶€í„°ì˜ ì¹¼ìŠ˜ ê³µê¸‰ ì¤‘ë‹¨.\n4. **ê²°ê³¼:** ì•„ê¸°ì˜ ë¶€ê°‘ìƒì„ ì€ ì—¬ì „íˆ ì–µì œëœ ìƒíƒœë¼ PTHë¥¼ ëª» ë§Œë“¦ â†’ ê¸‰ê²©í•œ ì €ì¹¼ìŠ˜í˜ˆì¦ ë°œìƒ â†’ **Seizure.**\n5. **ì¹˜ë£Œ:** ì•„ê¸°ì˜ ë¶€ê°‘ìƒì„ ì´ ê¹¨ì–´ë‚  ë•Œê¹Œì§€ ì¹¼ìŠ˜ ë³´ì¶© (ì¼ì‹œì  í˜„ìƒ).\n---\n## 5. ìˆ˜ìˆ  ì „ êµ­ì†Œí™” (Pre-op Localization)\n- **Sestamibi Scan (Technetium-99m):**\n    - ë¶€ê°‘ìƒì„  ì„ ì¢…(Adenoma)ì€ ë¯¸í† ì½˜ë“œë¦¬ì•„ê°€ í’ë¶€í•˜ì—¬ ë°©ì‚¬ì„± ì¶”ì ìë¥¼ í¡ìˆ˜, ìŠ¤ìº”ìƒ í¬ë¦¬ìŠ¤ë§ˆìŠ¤ íŠ¸ë¦¬ì²˜ëŸ¼ ë°ê²Œ ë¹›ë‚¨.\n    - ìˆ˜ìˆ  ì „ ì ˆê°œ ìœ„ì¹˜ë¥¼ íŒŒì•…í•˜ëŠ” í‘œì¤€ ë°©ë²•.\n---\n## 6. â˜… Surgical Indications (ìˆ˜ìˆ  ì ì‘ì¦)\nì¦ìƒì´ ìˆëŠ” í™˜ìëŠ” ë¬´ì¡°ê±´ ìˆ˜ìˆ ì…ë‹ˆë‹¤. ì¤‘ìš”í•œ ê²ƒì€ **ë¬´ì¦ìƒ(Asymptomatic)** í™˜ìì˜ ìˆ˜ìˆ  ê¸°ì¤€ì…ë‹ˆë‹¤. (ë°˜ë“œì‹œ ì•”ê¸°!)\n1. **Age:** **50ì„¸ ë¯¸ë§Œ** (ì Šì€ í™˜ìëŠ” ì¥ê¸°ì  í•©ë³‘ì¦ ì˜ˆë°©ì„ ìœ„í•´ ìˆ˜ìˆ ).\n2. **Calcium Level:** ì •ìƒ ìƒí•œì¹˜ë³´ë‹¤ **1 mg/dL ì´ìƒ** ë†’ì„ ë•Œ. (ì˜ˆ: cut-off 10.2ì¸ë° 11.2 ì´ìƒì¼ ë•Œ)\n    - ê¸‰ì„± ê³ ì¹¼ìŠ˜í˜ˆì¦ ìœ„ê¸°(Dehydration, Confusion) ìœ„í—˜ ë•Œë¬¸.\n3. **Kidney (ì‹ ì¥):**\n    - **GFR < 60** (Stage 3 CKD ì´ìƒ).\n    - ì˜ìƒ ê²€ì‚¬(CT, US, X-ray)ìƒ **ê²°ì„(Stone)**ì´ë‚˜ **ì„íšŒí™”(Nephrocalcinosis)** ë°œê²¬ ì‹œ (ë¬´ì¦ìƒì´ë¼ë„).\n4. **Bone (ë¼ˆ):**\n    - **ê³¨ë‹¤ê³µì¦ (Osteoporosis):** DEXA scan T-score **< -2.5** (Lumbar, Hip, Femoral neck, Distal radius).\n    - **ì·¨ì•½ ê³¨ì ˆ (Fragility Fracture)** ë³‘ë ¥ (ì†ëª© ê³¨ì ˆ ë“±).\n5. **Urine:** 24ì‹œê°„ ì†Œë³€ ì¹¼ìŠ˜ **> 400 mg/day** (ê²°ì„ ìƒì„± ìœ„í—˜).\n---\n## 7. Secondary & Tertiary Hyperparathyroidism (ì‹ ë¶€ì „ í™˜ì)\nì£¼ë¡œ ë§Œì„± ì‹ ë¶€ì „(CKD) ë˜ëŠ” íˆ¬ì„ í™˜ìì—ê²Œ ë°œìƒí•©ë‹ˆë‹¤.\n### Secondary Hyperparathyroidism\n- **ê¸°ì „:** ì‹ ì¥ ê¸°ëŠ¥ ì €í•˜ â†’ ë¹„íƒ€ë¯¼ D í™œì„±í™” ì‹¤íŒ¨ & ì¸ì‚°(Phosphate) ë°°ì¶œ ì‹¤íŒ¨ â†’ **High Phosphate**ê°€ ì¹¼ìŠ˜ê³¼ ê²°í•©í•´ ì¹¼ìŠ˜ ìˆ˜ì¹˜ ë–¨ì–´ëœ¨ë¦¼ â†’ ë³´ìƒ ì‘ìš©ìœ¼ë¡œ **PTH ìƒìŠ¹**.\n- **íŠ¹ì§•:** ë¶€ê°‘ìƒì„ ì´ \"ì‹œí‚¤ëŠ” ëŒ€ë¡œ ì¼í•˜ëŠ”\" ìƒíƒœ.\n### Tertiary Hyperparathyroidism\n- **ê¸°ì „:** Secondary ìƒíƒœê°€ ë„ˆë¬´ ì˜¤ë˜ ì§€ì†(ë§Œì„± ìê·¹)ë˜ì–´ ë¶€ê°‘ìƒì„ ì´ **ììœ¨ì„±(Autonomous)**ì„ íšë“. \"Rogue\" ìƒíƒœê°€ ë¨.\n- **Labs:** â˜… **High Calcium**, **High Phosphate**, **Massive PTH** (>800~1000 pg/mL).\n- **ìœ„í—˜ì„±:** ì¹¼ìŠ˜ê³¼ ì¸ì‚°ì´ ëª¨ë‘ ë†’ì•„ í˜ˆì•¡ì´ í¬í™”ë¨ â†’ ì¡°ì§ì— ì„íšŒ ì¹¨ì°©.\n### ğŸš¨ Calciphylaxis (Calcific Uremic Arteriolopathy)","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-81","focus_area":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","tags":["usmle-step2","core"]}
{"chunk_type":"transcript_chunk","text":"- **ì •ì˜:** í”¼ë¶€ì˜ ì‘ì€ í˜ˆê´€ë“¤ì´ ì„íšŒí™”ë˜ì–´ ë§‰íˆëŠ” ì‘ê¸‰ ìƒí™©.\n- **ì¦ìƒ:** ë³´ë¼ìƒ‰(Violet) í”¼ë¶€ ë³‘ë³€, ê´´ì‚¬(Necrosis), ê¶¤ì–‘(Gangrene). ì‚¬ë§ë¥  ë§¤ìš° ë†’ìŒ.\n- **ê¸°íƒ€ ìˆ˜ìˆ  ì ì‘ì¦:**\n    - **Calciphylaxis** ë°œìƒ ì‹œ ì¦‰ì‹œ ìˆ˜ìˆ  (Source of PTH ì œê±°).\n    - ë‚œì¹˜ì„± ë¼ˆ í†µì¦ (Intractable bone pain).\n    - **ì‹¬í•œ ê°€ë ¤ì›€ì¦ (Severe Pruritus):** í”¼ë¶€ì— ì¹¼ìŠ˜/ì¸ì‚° ì¹¨ì°©ìœ¼ë¡œ ì¸í•´ ë°œìƒ.\n---\n## 8. Post-surgical Hypoparathyroidism (ìˆ˜ìˆ  í›„ ë¶€ê°‘ìƒì„  ê¸°ëŠ¥ ì €í•˜ì¦)\n- **ì›ì¸:** ê°‘ìƒì„ /ë¶€ê°‘ìƒì„  ì ˆì œìˆ  ì¤‘ ì‹¤ìˆ˜ë¡œ ì„ ì„ ì œê±°í•˜ê±°ë‚˜ í˜ˆë¥˜ë¥¼ ì°¨ë‹¨í•¨.\n- **ì¹˜ë£Œ:** ì¹¼ìŠ˜ + ë¹„íƒ€ë¯¼ D ë³´ì¶©.\n### âš ï¸ The Danger Zone: Calcium-Phosphate Product\n- **ê³µì‹:** Serum Calcium Ã— Serum Phosphate.\n- **ëª©í‘œ:** ì´ ê°’ì„ **55 ë¯¸ë§Œ**ìœ¼ë¡œ ìœ ì§€í•´ì•¼ í•¨.\n- **ìœ„í—˜:** 55ë¥¼ ì´ˆê³¼í•˜ë©´ ì—°ì¡°ì§ ì„íšŒí™” ìœ„í—˜ ê¸‰ì¦.\n- **Basal Ganglia Calcification:**\n    - ë‡Œì˜ ê¸°ì €í•µì— ì„íšŒí™” ë°œìƒ ê°€ëŠ¥.\n    - **ì¦ìƒ:** **íŒŒí‚¨ìŠ¨ë³‘ ìœ ì‚¬ ì¦ìƒ (Parkinsonian symptoms)**, ë–¨ë¦¼(Tremor), ë¬´ë„ë³‘(Chorea) ë“± ì¶”ì²´ì™¸ë¡œ ì¦ìƒ ìœ ë°œ.\n    - ë‹¨ìˆœíˆ ì¹¼ìŠ˜ë§Œ ì£¼ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ ì¸ì‚° ìˆ˜ì¹˜ë„ ì¡°ì ˆ(Phosphate binders)í•˜ëŠ” ê· í˜•ì´ í•„ìš”í•¨.\n---\n## 9. ğŸ”¥ Rapid Fire Recap\nê°•ì˜ ë§ˆì§€ë§‰ì— ì •ë¦¬ëœ í•µì‹¬ ìš”ì•½ì…ë‹ˆë‹¤.\n1. **Primary Hyperpara Labs:** High Calcium + High/Normal PTH.\n2. **FHH êµ¬ë¶„:** **Urine Calcium** (PrimaryëŠ” High, FHHëŠ” Low, Ratio < 0.01). **FHHëŠ” ìˆ˜ìˆ  ì•ˆ í•¨.**\n3. **Neonatal Seizure + Low PTH:** **Maternal FHH** (ì—„ë§ˆì˜ ê³ ì¹¼ìŠ˜ì´ íƒœì•„ ì„ ì„ ì–µì œ).\n4. **Asymptomatic ìˆ˜ìˆ  ì ì‘ì¦ (ë°˜ë“œì‹œ ì•”ê¸°):**\n    - Age < 50\n    - Calcium > 1 mg/dL above normal\n    - GFR < 60 or Stones\n    - Osteoporosis (T-score < -2.5) or Fracture\n    - Urine Calcium > 400 mg/day\n5. **Tertiary Hyperpara:** Renal failure í™˜ì, Autonomous glands, High Ca/High Phos.\n    - **ìœ„í—˜:** **Calciphylaxis** (í”¼ë¶€ ê´´ì‚¬), ì‹¬í•œ ê°€ë ¤ì›€ì¦ â†’ ìˆ˜ìˆ  í•„ìš”.\n6. **Hypopara Treatment Goal:** Calcium Ã— Phosphate product **< 55** ìœ ì§€ (Basal Ganglia ì„íšŒí™” ë° íŒŒí‚¨ìŠ¨ ì¦ìƒ ì˜ˆë°©).\n---\n### ğŸ“ Final Thought\nìˆ˜ìˆ  ì ì‘ì¦(íŠ¹íˆ ë¬´ì¦ìƒ í™˜ì)ì€ ë‹¨ìˆœí•œ ìˆ«ìê°€ ì•„ë‹ˆë¼ **ìœ„í—˜ë„ ê³„ì¸µí™”(Risk Stratification)** ë„êµ¬ì…ë‹ˆë‹¤. ì¦ìƒì´ ì—†ë”ë¼ë„ ë¼ˆì™€ ì‹ ì¥ì— ì˜êµ¬ì ì¸ ì†ìƒì´ ì˜¤ê¸° ì „ì— \"ì§€ë¶•ì´ ìƒˆê¸° ì „ì— ê³ ì¹˜ëŠ”(Preventative Medicine)\" ê°œë…ìœ¼ë¡œ ì ‘ê·¼í•´ì•¼ í•©ë‹ˆë‹¤.\n---\n# ğŸ©º USMLE Step 2 Endocrine: The \"Deep Dive\" Frameworks\nì´ë²ˆ ë”¥ë‹¤ì´ë¸Œì—ì„œëŠ” ë‹¨ìˆœí•œ ì‚¬ì‹¤ ì•”ê¸°ê°€ ì•„ë‹Œ, **\"Next Best Step\"**ì„ ê²°ì •í•˜ê¸° ìœ„í•œ **ì˜ì‚¬ê²°ì • ë‚˜ë¬´(Decision Tree)**ë¥¼ ë§Œë“œëŠ” ë° ì§‘ì¤‘í•©ë‹ˆë‹¤. ì‹¤ì œ ì‹œí—˜ì´ë‚˜ ë³‘ë™(Wards)ì—ì„œ í™˜ìë¥¼ ë§ˆì£¼í–ˆì„ ë•Œ í•„ìš”í•œ ìƒì¡´ ë©”ì»¤ë‹ˆì¦˜ì„ ë‹¤ë£¹ë‹ˆë‹¤. ë˜í•œ, ì²­ì·¨ì ìš”ì²­ì— ë”°ë¼ **Milk-Alkali Syndrome** (ì†ŒìŠ¤ í…ìŠ¤íŠ¸ì— í•œ ì¤„ë§Œ ìˆì–´ ì œì™¸ë¨) ëŒ€ì‹  **Hypoglycemia Associated Autonomic Failure**ë¥¼ ê¹Šì´ ìˆê²Œ ë‹¤ë£¹ë‹ˆë‹¤.\n## 1. Introduction: Mental Frameworks ğŸ§ \n- **í•µì‹¬ ëª©í‘œ:** ê±°ëŒ€í•œ ì‚¬ì‹¤ë“¤ì˜ ë‚˜ì—´ì„ ì™¸ìš°ëŠ” ê²ƒì´ ì•„ë‹ˆë¼, í™˜ìê°€ ì£¼ì–´ì¡Œì„ ë•Œ **\"ë‹¤ìŒì— ë¬´ì—‡ì„ í•  ê²ƒì¸ê°€?\"**ë¥¼ ê²°ì •í•˜ëŠ” ëŠ¥ë ¥ì„ ê¸°ë¥´ëŠ” ê²ƒ.\n- **ì ‘ê·¼ ë°©ì‹:** ë‡Œí•˜ìˆ˜ì²´(Pituitary), ê°‘ìƒì„ (Thyroid), ë¶€ê°‘ìƒì„ (Parathyroid), ë¶€ì‹ (Adrenal)ì— ëŒ€í•œ í•µì‹¬ í”„ë ˆì„ì›Œí¬ë¥¼ êµ¬ì¶•í•˜ê³ , ë‹¹ë‡¨ë³‘(Diabetes) íŒŒíŠ¸ì—ì„œëŠ” ììœ¨ì‹ ê²½ê³„ ë¶€ì „(Autonomic failure)ì„ ì§‘ì¤‘ì ìœ¼ë¡œ ë¶„ì„í•©ë‹ˆë‹¤.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-101","focus_area":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","tags":["usmle-step2","core","treatment","tree"]}
{"chunk_type":"transcript_chunk","text":"---\n## 2. Pituitary Gland (ë‡Œí•˜ìˆ˜ì²´) ğŸ¯\n### ğŸ§  Prolactinoma (í”„ë¡œë½í‹´ì„ ì¢…)\nê°€ì¥ ë¨¼ì € **\"Rule of 200\"**ì„ ê¸°ì–µí•´ì•¼ í•©ë‹ˆë‹¤.\n- **ì§„ë‹¨ ê¸°ì¤€:** í˜ˆì²­ Prolactin ìˆ˜ì¹˜ê°€ **> 200**ì´ë©´ Prolactinomaì¼ í™•ë¥ ì´ ì‚¬ì‹¤ìƒ ì§„ë‹¨ì (Virtually diagnostic)ì…ë‹ˆë‹¤.\n- **âš ï¸ The Exam Trap (ì‹œí—˜ì˜ í•¨ì •):** MRIë¥¼ ì°ìœ¼ëŸ¬ í™˜ìë¥¼ ë³´ë‚´ê¸° ì „ì— ë°˜ë“œì‹œ **ë©ˆì¶°ì•¼ í•©ë‹ˆë‹¤.**\n    - **Rule Out First:**\n        1. **Renal Insufficiency (ì‹ ë¶€ì „):** Prolactinì€ ì‹ ì¥ì—ì„œ ì œê±°ë©ë‹ˆë‹¤. ì‹ ë¶€ì „ ì‹œ ìˆ˜ì¹˜ê°€ ìƒìŠ¹í•©ë‹ˆë‹¤. â†’ **Creatinine ì²´í¬.**\n        2. **Hypothyroidism (ê°‘ìƒì„ ê¸°ëŠ¥ì €í•˜ì¦):** ê°‘ìƒì„ ì´ ì‘ë™í•˜ì§€ ì•Šìœ¼ë©´ ì‹œìƒí•˜ë¶€ê°€ TRHë¥¼ ë¶„ë¹„í•©ë‹ˆë‹¤. TRHëŠ” TSHë¿ë§Œ ì•„ë‹ˆë¼ Prolactinë„ ìê·¹í•©ë‹ˆë‹¤. â†’ **TSH ì²´í¬.**\n- **Next Best Step:** MRIê°€ ì•„ë‹ˆë¼ **Creatinineê³¼ TSH í™•ì¸**ì´ ìš°ì„ ì…ë‹ˆë‹¤.\n- **ì¹˜ë£Œ (Treatment):**\n    - MRIì—ì„œ ê±°ëŒ€ì„ ì¢…(Macroprolactinoma)ì´ ë³´ì—¬ë„ ìˆ˜ìˆ (Surgery)ì´ 1ì°¨ ì¹˜ë£Œê°€ ì•„ë‹™ë‹ˆë‹¤. â˜…\n    - **1ì°¨ ì¹˜ë£Œ:** Medical therapy (Dopamine Agonists). ì˜ˆ: **Cabergoline**.\n    - ë„íŒŒë¯¼ì€ í”„ë¡œë½í‹´ì„ ì–µì œí•˜ë©°, ì•½ë¬¼ ì¹˜ë£Œë§Œìœ¼ë¡œë„ ì¢…ì–‘ í¬ê¸°ë¥¼ ì¤„ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ìˆ˜ìˆ ì€ ì•½ë¬¼ ì‹¤íŒ¨ë‚˜ ì‹œì•¼ ê²°ì†ì´ ì§€ì†ë  ë•Œì˜ \"ë°±ì—… í”Œëœ\"ì…ë‹ˆë‹¤.\n### ğŸ’§ Water Balance: SIADH vs. Diabetes Insipidus (DI)\në§ì€ ì‚¬ëŒë“¤ì´ ì–´ë ¤ì›Œí•˜ì§€ë§Œ **\"Logic Gate\"**ë¥¼ ë”°ë¥´ë©´ í•´ê²°ë©ë‹ˆë‹¤.\n1. **Step 1: Definition of Polyuria**\n    - ì†Œë³€ëŸ‰ì´ í•˜ë£¨ **3L ì´ìƒ**ì´ì–´ì•¼ ì§„ì •í•œ ë‹¤ë‡¨(True Polyuria)ì…ë‹ˆë‹¤.\n2. **Step 2: Urine Osmolality (ì†Œë³€ ì‚¼íˆ¬ì••)**\n    - **Concentrated (ë†ì¶•):** ì‚¼íˆ¬ì„± ì´ë‡¨(Osmotic diuresis). ì˜ˆ: ë‹¹ë‡¨ë³‘(Diabetes Mellitus)ì—ì„œ í¬ë„ë‹¹ì´ ë¬¼ì„ ëŒê³  ë‚˜ê°€ëŠ” ê²½ìš°.\n    - **Dilute (í¬ì„):** ë§¹ë¬¼(Pure water)ì„ ë°°ì¶œí•˜ëŠ” ê²½ìš°. ì´ê²ƒì´ **Water Diuresis**ì…ë‹ˆë‹¤.\n### âš–ï¸ DI (ìš”ë¶•ì¦) vs. Primary Polydipsia (ì¼ì°¨ì„± ë‹¤ê°ˆì¦) êµ¬ë³„ë²•\nê°€ì¥ ì¤‘ìš”í•œ ë‹¨ì„œëŠ” **Sodium (ë‚˜íŠ¸ë¥¨)** ìˆ˜ì¹˜ì…ë‹ˆë‹¤.\n| êµ¬ë¶„ | ë³‘íƒœìƒë¦¬ | Sodium (Na) ìˆ˜ì¹˜ | ë¹„ê³  |\n| --- | --- | --- | --- |\n| **Primary Polydipsia** | ë¬¼ì„ ë„ˆë¬´ ë§ì´ ë§ˆì…”ì„œ í˜ˆì•¡ì´ í¬ì„ë¨ | **Hyponatremia (ì €ë‚˜íŠ¸ë¥¨)** | Waterlogged status |\n| **Central DI** | ë‡Œì—ì„œ ADHë¥¼ ëª» ë§Œë“¦. ë¬¼ì„ ë‹¤ ìƒì–´ë²„ë¦¬ê³  í˜ˆì•¡ì´ ë†ì¶•ë¨ | **Hypernatremia (ê³ ë‚˜íŠ¸ë¥¨)** | ê°ˆì¦ ê¸°ì „ì´ ê³ ì¥ ë‚¬ì„ ìˆ˜ ìˆìŒ |\n| **Nephrogenic DI** | ì‹ ì¥ì´ ADHë¥¼ ë¬´ì‹œí•¨. ê°ˆì¦ ê¸°ì „ì€ ì •ìƒì´ë¼ ë¬¼ì„ ë§ˆì…” ë³´ìƒí•¨ | **Normal Na** | ë³´í†µ ë‚˜íŠ¸ë¥¨ ìˆ˜ì¹˜ ì •ìƒ ìœ ì§€ |\n---\n## 3. Thyroid (ê°‘ìƒì„ ) ğŸ¦‹\n### ğŸ¤° Thyroid in Pregnancy (ì„ì‹ ê³¼ ê°‘ìƒì„ )\nì„ì‹ ì€ ìƒë¦¬í•™ì ìœ¼ë¡œ **Hyperthyroidism(ê°‘ìƒì„ ê¸°ëŠ¥í•­ì§„ì¦)ì„ ëª¨ë°©(Mimic)**í•©ë‹ˆë‹¤.\n- **Estrogen ì¦ê°€:** TBG(Thyroid Binding Globulin)ë¥¼ ì¦ê°€ì‹œì¼œ **Total T4** ìˆ˜ì¹˜ë¥¼ ë†’ì…ë‹ˆë‹¤.\n- **hCG íš¨ê³¼:** hCGëŠ” TSHì™€ êµ¬ì¡°ê°€ ë¹„ìŠ·í•˜ì—¬ ê°‘ìƒì„ ì„ ìê·¹í•©ë‹ˆë‹¤. ì´ë¡œ ì¸í•´ ì‹¤ì œ **TSH ìˆ˜ì¹˜ëŠ” ë‚®ì•„ì§‘ë‹ˆë‹¤.**\n- **ì •ìƒ ì†Œê²¬:** ì„ì‚°ë¶€(íŠ¹íˆ 1ë¶„ê¸°)ëŠ” **High Total T4, Low TSH**ë¥¼ ë³´ì´ëŠ” ê²ƒì´ ì •ìƒì…ë‹ˆë‹¤. (Gestational Transient Thyrotoxicosis) â†’ ì¹˜ë£Œí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.\n### Graves' Disease in Pregnancy (ì„ì‹  ì¤‘ ê·¸ë ˆì´ë¸ŒìŠ¤ë³‘)\në§Œì•½ ì§„ì§œ ê·¸ë ˆì´ë¸ŒìŠ¤ë³‘ì´ë¼ë©´ ì¹˜ë£Œì œê°€ ë§¤ìš° ê¹Œë‹¤ë¡­ìŠµë‹ˆë‹¤.\n- **1st Trimester:** **PTU** (Methimazoleì€ ê¸°í˜• ìœ ë°œ ê°€ëŠ¥ì„± - Teratogen). \"P for Pregnancy, P for PTU\".\n- **2nd Trimester ì´í›„:** **Methimazole**ë¡œ êµì²´ (PTUëŠ” ê°„ ë…ì„± ìœ„í—˜ - Black box warning). â˜…\n### Hypothyroidism in Pregnancy (ì„ì‹  ì¤‘ ê°‘ìƒì„ ê¸°ëŠ¥ì €í•˜ì¦)","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-121","focus_area":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","tags":["usmle-step2","core","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"- **íƒœì•„ ìœ„í—˜:** íƒœì•„ì˜ ë‡Œ ë°œë‹¬ì€ ëª¨ì²´ì˜ ê°‘ìƒì„  í˜¸ë¥´ëª¬ì— ì˜ì¡´í•©ë‹ˆë‹¤.\n- **ì¡°ì¹˜:** ì„ì‹  í™•ì¸ ì¦‰ì‹œ **Levothyroxine ìš©ëŸ‰ì„ 30% ì¦ëŸ‰**í•´ì•¼ í•©ë‹ˆë‹¤. â˜…\n    - **ì ˆëŒ€ Lab ê²°ê³¼ë¥¼ ê¸°ë‹¤ë¦¬ì§€ ë§ˆì„¸ìš”.** ì¦‰ì‹œ ì¦ëŸ‰ í›„ 4ì£¼ ë’¤ TSH í™•ì¸.\n### ğŸ” Thyroid Nodules (ê°‘ìƒì„  ê²°ì ˆ)\nê²°ì ˆì´ ë§Œì ¸ì§ˆ ë•Œ ê°€ì¥ ë¨¼ì € í•´ì•¼ í•  ì¼ì€ **TSH ì¸¡ì •**ê³¼ **Ultrasound(ì´ˆìŒíŒŒ)**ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ **TSH**ê°€ ì˜ì‚¬ê²°ì •ì˜ ê°ˆë¦¼ê¸¸(Fork in the road)ì…ë‹ˆë‹¤.\n- **TSH Low (ë‚®ìŒ):** ê°‘ìƒì„ ì´ ê³¼ë‹¤í™œë™ ì¤‘. â†’ **Scintigraphy (Radioiodine scan)** ì‹œí–‰.\n    - **Hot Nodule:** ê¸°ëŠ¥ í•­ì§„ ê²°ì ˆ. ì•”ì¼ í™•ë¥  ê±°ì˜ ì—†ìŒ.\n    - **Cold Nodule:** ê¸°ëŠ¥ ì €í•˜. ì•…ì„± ê°€ëŠ¥ì„± ìˆìŒ.\n- **TSH Normal or High:** ìŠ¤ìº”ì€ ì“¸ëª¨ì—†ìŒ. â†’ ë°”ë¡œ **Ultrasound** íŠ¹ì§• í™•ì¸ í›„ ì˜ì‹¬ìŠ¤ëŸ¬ìš°ë©´ **FNA (ì„¸ì¹¨í¡ì¸ìƒê²€)** ì‹œí–‰. â˜…\n---\n## 4. Parathyroid (ë¶€ê°‘ìƒì„ ) ğŸ¦´\n### ğŸ¥› Hypercalcemia (ê³ ì¹¼ìŠ˜í˜ˆì¦)\nHigh Calciumì€ ë³´í†µ High PTH(Primary Hyperparathyroidism)ë¥¼ ì˜ë¯¸í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ìœ ì „ì  ëª¨ë°© ì§ˆí™˜ì¸ **FHH (Familial Hypocalciuric Hypercalcemia)**ë¥¼ ì£¼ì˜í•´ì•¼ í•©ë‹ˆë‹¤.\n- **ê°ë³„ í¬ì¸íŠ¸:** **Urine Calcium (ì†Œë³€ ì¹¼ìŠ˜)**.\n    - **FHH:** ì‹ ì¥ì´ ìœ ì „ì ìœ¼ë¡œ ì¹¼ìŠ˜ì„ ì¬í¡ìˆ˜(Hoarding)í•˜ë ¤ í•¨. â†’ ì†Œë³€ ì¹¼ìŠ˜ ë§¤ìš° ë‚®ìŒ. (**Calcium/Creatinine clearance ratio < 0.01**)\n    - **ìˆ˜ìˆ  ê¸ˆì§€:** FHH í™˜ìì—ê²Œ ë¶€ê°‘ìƒì„  ì ˆì œìˆ ì€ íš¨ê³¼ê°€ ì—†ìœ¼ë¯€ë¡œ ì ˆëŒ€ í•˜ë©´ ì•ˆ ë©ë‹ˆë‹¤.\n### ğŸ‘¶ Maternal FHH Scenario (ì‹¬í™”)\n- ì‚°ëª¨ê°€ FHHì¼ ê²½ìš°(ê³ ì¹¼ìŠ˜í˜ˆì¦), íƒœì•„ëŠ” ìê¶ ë‚´ì—ì„œ ê³ ì¹¼ìŠ˜ í™˜ê²½ì— ë…¸ì¶œë©ë‹ˆë‹¤.\n- íƒœì•„ì˜ ë¶€ê°‘ìƒì„ ì€ ì–µì œ(Sleep)ë©ë‹ˆë‹¤.\n- **ì¶œìƒ í›„:** ëª¨ì²´ì˜ ì¹¼ìŠ˜ ê³µê¸‰ì´ ëŠê¸°ë©´, ì•„ê¸°ì˜ ë¶€ê°‘ìƒì„ ì´ ê¹¨ì–´ë‚˜ì§€ ëª»í•´ **Severe Hypocalcemia (ë°œì‘, ê²½ë ¨)**ê°€ ë°œìƒí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. (Transient Hypoparathyroidism)\n---\n## 5. Adrenal Gland (ë¶€ì‹ ) âš¡\n### ğŸ©¸ Hypertension & Conn's Syndrome (Primary Hyperaldosteronism)\n- **ì¦ìƒ:** ì¡°ì ˆë˜ì§€ ì•ŠëŠ” ê³ í˜ˆì•• + **Low Potassium (ì €ì¹¼ë¥¨í˜ˆì¦)**.\n- **ì„ ë³„ ê²€ì‚¬:** Aldosterone/Renin Ratio > 20.\n- **Aldosterone Escape:** â˜…\n    - ì•Œë„ìŠ¤í…Œë¡ ì€ ì†Œê¸ˆê³¼ ë¬¼ì„ ì¡ì•„ë‘ì§€ë§Œ, í™˜ìë“¤ì€ **ë¶€ì¢…(Edema)ì´ ì—†ìŠµë‹ˆë‹¤.**\n    - ì´ìœ : í˜ˆë¥˜ëŸ‰ ì¦ê°€ë¥¼ ì‹¬ì¥ì´ ê°ì§€í•˜ì—¬ **ANP (Atrial Natriuretic Peptide)**ë¥¼ ë¶„ë¹„, ì‹ ì¥ì´ ê°•ì œë¡œ ì†Œê¸ˆê³¼ ë¬¼ì„ ë°°ì¶œí•˜ê²Œ ë§Œë“­ë‹ˆë‹¤(Pressure Natriuresis). â†’ ë¶€ì¢…ì€ ì—†ì§€ë§Œ ê³ í˜ˆì••ê³¼ ì €ì¹¼ë¥¨í˜ˆì¦ì€ ë‚¨ìŠµë‹ˆë‹¤.\n### ğŸ“‰ Adrenal Insufficiency (Addison's Disease)\n- **ì¦ìƒ:** ì²´ì¤‘ ê°ì†Œ, ì˜¤ì‹¬, ê³¼ìƒ‰ì†Œì¹¨ì°©(Darker skin - ACTH ì¦ê°€ ë•Œë¬¸).\n- **Lab íŠ¹ì§•:** Conn'sì˜ ë°˜ëŒ€. **Hyponatremia (ì €ë‚˜íŠ¸ë¥¨), Hyperkalemia (ê³ ì¹¼ë¥¨)**.\n- **Hidden Pearl:** **Eosinophilia (í˜¸ì‚°êµ¬ì¦ê°€ì¦)**. ì½”ë¥´í‹°ì†”ì´ ì—†ìœ¼ë©´ í˜¸ì‚°êµ¬ê°€ ì–µì œë˜ì§€ ì•Šì•„ ìˆ˜ì¹˜ê°€ ì˜¤ë¦…ë‹ˆë‹¤. â˜…\n- **ì§„ë‹¨:** **Cosyntropin (Synthetic ACTH) Stimulation Test**.\n    - ì •ìƒ: ì½”ë¥´í‹°ì†” ë¶„ë¹„ ì¦ê°€.\n    - ë¶€ì „: ë°˜ì‘ ì—†ìŒ.\n- **ì›ì¸ ì•½ë¬¼:** **Etomidate** (ë§ˆì·¨ ìœ ë„ì œ)ëŠ” ì½”ë¥´í‹°ì†” ìƒì„± íš¨ì†Œë¥¼ ì–µì œí•˜ì—¬, ìœ„ë…í•œ í™˜ìë¥¼ ë¶€ì‹  ìœ„ê¸°(Adrenal Crisis)ë¡œ ëª°ì•„ë„£ì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n---\n## 6. Diabetes & Autonomic Failure ğŸ¬\n### âš ï¸ Hypoglycemia Associated Autonomic Failure","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-141","focus_area":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","tags":["usmle-step2","core"]}
{"chunk_type":"transcript_chunk","text":"- **ê¸°ì „:** ë°˜ë³µì ì¸ ì €í˜ˆë‹¹ì´ ë°œìƒí•˜ë©´ ì‹ ì²´ì˜ ê²½ê³  ì‹œìŠ¤í…œ(ì¹´í…Œì½œì•„ë¯¼ ë¶„ë¹„ - ë–¨ë¦¼, ì‹ì€ë•€, ë‘ê·¼ê±°ë¦¼)ì´ ë¬´ëŒì§‘ë‹ˆë‹¤.\n- **ê²°ê³¼:** **Hypoglycemia Unawareness**. í™˜ìëŠ” ì „ì¡°ì¦ìƒ ì—†ì´ ë°”ë¡œ ì˜ì‹ì„ ìƒìŠµë‹ˆë‹¤.\n- **ì•…ìˆœí™˜:** í•œ ë²ˆì˜ ì €í˜ˆë‹¹ ì—í”¼ì†Œë“œê°€ ë‹¤ìŒ ë©°ì¹ ê°„ ììœ¨ì‹ ê²½ ë°˜ì‘ì„ ë‘”í™”ì‹œí‚µë‹ˆë‹¤.\n### ğŸ¤¢ Gastroparesis (ìœ„ë¬´ë ¥ì¦)\n- **ì›ì¸:** ë¯¸ì£¼ì‹ ê²½(Vagus nerve) ì†ìƒ. ìœ„ê°€ ë¹„ì›Œì§€ì§€ ì•ŠìŒ.\n- **ì¦ìƒ:** ëª‡ ì…ë§Œ ë¨¹ì–´ë„ ë°°ê°€ ë¶€ë¦„(Early satiety), ì˜¤ì‹¬.\n- **Post-prandial Hypoglycemia (ì‹í›„ ì €í˜ˆë‹¹):** â˜…\n    - **Timing Mismatch:** ì¸ìŠë¦°(ì†íš¨ì„±)ì€ 15ë¶„ ë§Œì— ì‘ìš©í•˜ì§€ë§Œ, ìœ„ë¬´ë ¥ì¦ ë•Œë¬¸ì— ìŒì‹ì€ ì†Œí™”ë˜ì§€ ì•Šê³  ìœ„ì¥ì— ë‚¨ì•„ìˆìŠµë‹ˆë‹¤.\n    - ìŒì‹ì´ í¡ìˆ˜ë˜ê¸°ë„ ì „ì— ì¸ìŠë¦°ì´ ì‘ìš©í•˜ì—¬ **ì‹ì‚¬ í›„ ì˜¤íˆë ¤ í˜ˆë‹¹ì´ ê¸‰ê²©íˆ ë–¨ì–´ì§€ëŠ”(Crash)** í˜„ìƒì´ ë°œìƒí•©ë‹ˆë‹¤.\n---\n## 7. Additional High-Yield Concepts ğŸŒŸ\n### ğŸ“‰ Subclinical Hypothyroidism\n- **ìƒíƒœ:** TSH ë†’ìŒ, T4 ì •ìƒ.\n- **ì¹˜ë£Œ ê¸°ì¤€:**\n    - **TSH > 10:** ì¹˜ë£Œí•¨.\n    - **TSH 7~10:** **ë‚˜ì´(Age)**ë¥¼ ë´…ë‹ˆë‹¤.\n        - **ì Šì€ í™˜ì (<70ì„¸):** ì¹˜ë£Œ ê³ ë ¤.\n        - **ë…¸ì¸ í™˜ì (>70ì„¸):** **\"Do Not Treat\"**. ì¹˜ë£Œê°€ ì˜¤íˆë ¤ í•´ê°€ ë  ìˆ˜ ìˆìŒ (ì‹¬ë°©ì„¸ë™-Afib, ë¼ˆ ì†ì‹¤ ìœ ë°œ). ê´€ì°°ë§Œ í•¨.\n### ğŸ¥ Euthyroid Sick Syndrome\n- **ìƒí™©:** ICUì— ìˆëŠ” ì¤‘í™˜ìì˜ ê°‘ìƒì„  ìˆ˜ì¹˜ê°€ ì—‰ë§ì„ (Low T3, Low TSH).\n- **ëŒ€ì²˜:** **\"Do Not Treat\"**.\n    - ì´ëŠ” ì‹ ì²´ì˜ ì ì‘ ë°˜ì‘(Adaptive response)ì…ë‹ˆë‹¤. ëŒ€ì‚¬ë¥¼ ëŠ¦ì¶° ìƒì¡´í•˜ë ¤ëŠ” ê¸°ì „ì…ë‹ˆë‹¤.\n    - ì´ë•Œ í˜¸ë¥´ëª¬ì„ íˆ¬ì—¬í•˜ë©´ ì‚¬ë§ë¥ (Mortality)ì´ ì¦ê°€í•©ë‹ˆë‹¤.\n---","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-161","focus_area":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","tags":["usmle-step2","core"]}
{"chunk_type":"recap_summary","text":"## ğŸ”¥ Rapid Fire Recap (í•µì‹¬ ìš”ì•½)\n1. **Prolactin > 200:** MRI ì „ì— **Meds(ì•½ë¬¼), TSH, Creatinine** í™•ì¸.\n2. **Thyroid Nodule:** **TSH ë¨¼ì €**. Lowë©´ Scan, Normalì´ë©´ Biopsy.\n3. **Pregnant Hypothyroid:** ì¦‰ì‹œ **Levothyroxine 30% ì¦ëŸ‰**.\n4. **Hypercalcemia:** ìˆ˜ìˆ  ì „ **Urine Calcium** í™•ì¸í•˜ì—¬ FHH ë°°ì œ.\n5. **Sick Patient (Low Na, High K, Eosinophilia):** **Adrenal Insufficiency** ì˜ì‹¬. **Cosyntropin Test**ë¡œ í™•ì§„.\n6. **Subclinical Hypothyroid (TSH 7~10, >70ì„¸):** **ì¹˜ë£Œí•˜ì§€ ì•ŠìŒ (Watch and Wait).**\n7. **ICU Patient (Low T3/TSH):** **Euthyroid Sick Syndrome**. ì¹˜ë£Œí•˜ì§€ ì•ŠìŒ.\n---\n# USMLE Step 2 Endocrinology Deep Dive: Pharmacology & Management Framework\n## 1. Introduction: The Mental Framework ğŸ§ \nê°•ì˜ëŠ” ë‹¨ìˆœí•œ ì•”ê¸°ê°€ ì•„ë‹Œ **'ë…¼ë¦¬(Logic)'**ì™€ **'í”¼ë“œë°± ë£¨í”„(Feedback Loops)'**ë¥¼ ê°•ì¡°í•˜ë©° ì‹œì‘í•©ë‹ˆë‹¤. ë‚´ë¶„ë¹„í•™(Endocrinology)ì—ì„œì˜ ì§„ë‹¨ì€ ì£¼ë¡œ ì„¤ì •(Set-up)ì— ë¶ˆê³¼í•˜ë©°, ì‹¤ì œ ì‹œí—˜ì—ì„œ ìˆ˜í—˜ìƒë“¤ì„ ë–¨ì–´ëœ¨ë¦¬ëŠ” ì§„ì§œ ë¬¸ì œëŠ” **\"ë© ê²°ê³¼ê°€ ë‚˜ì˜¨ í›„ ë¬´ì—‡ì„ í•  ê²ƒì¸ê°€(Next Step)\"**ì— ìˆìŠµë‹ˆë‹¤.\n- **Context is Everything:** ë‚´ë¶„ë¹„í•™ì—ì„œëŠ” ì •ë‹µì— ê±°ëŒ€í•œ **ë³„í‘œ(Asterisk â˜…)**ê°€ ë¶™ìŠµë‹ˆë‹¤.\n    - ì¼ë°˜ì ì¸ í™˜ìì—ê²ŒëŠ” 'Gold Standard'ì¸ ì•½ë¬¼ì´ ì„ì‹ ë¶€ì—ê²ŒëŠ” ê¸°í˜•ì„ ìœ ë°œí•  ìˆ˜(Teratogen) ìˆê³ , 30ì„¸ í™˜ìë¥¼ ì‚´ë¦¬ëŠ” ì•½ì´ 75ì„¸ í™˜ìì—ê²ŒëŠ” ì¹˜ëª…ì ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n- **ë¡œë“œë§µ:** ë‡Œí•˜ìˆ˜ì²´(Pituitary) â†’ ê°‘ìƒì„ (Thyroid) â†’ ë¶€ì‹ (Adrenals) & ë¶€ê°‘ìƒì„ (Parathyroids) â†’ ë‹¹ë‡¨ ê´€ë¦¬(Diabetes Maintenance).\n---","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-171","focus_area":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","tags":["usmle-step2","core","recap","diagnosis","treatment"]}
{"chunk_type":"transcript_chunk","text":"## 2. The Pituitary: Prolactin & Water Balance ğŸ’§\n### A. Prolactinoma (The Detective Work) ğŸ•µï¸â€â™€ï¸\nProlactin ìˆ˜ì¹˜ê°€ ë†’ë‹¤ê³  í•´ì„œ ë¬´ì¡°ê±´ Prolactinoma(ì¢…ì–‘)ë¼ê³  ë‹¨ì • ì§“ê³  ì¹˜ë£Œë¥¼ ì‹œì‘í•˜ë©´ ì•ˆ ë©ë‹ˆë‹¤. **\"Rule out mimics\"**ê°€ ìš°ì„ ì…ë‹ˆë‹¤.\n- **â˜… The Mimics (í•¨ì •):**\n    - **ì„ì‹ (Pregnancy):** ê°€ì¥ ëª…ë°±í•œ ì›ì¸.\n    - **í•­ì •ì‹ ë³‘ ì•½ë¬¼(Antipsychotics):** ë„íŒŒë¯¼ ì–µì œ ê¸°ì „ ë•Œë¬¸.\n    - **ì‹ ë¶€ì „(Renal Insufficiency):** í˜¸ë¥´ëª¬ í´ë¦¬ì–´ëŸ°ìŠ¤(Clearance) ë¬¸ì œë¡œ í˜ˆì¤‘ ë†ë„ ì¶•ì . (ë‡Œí•˜ìˆ˜ì²´ì˜ ê³¼ìƒì„±ì´ ì•„ë‹˜)\n    - **ê°‘ìƒì„ ê¸°ëŠ¥ì €í•˜ì¦(Hypothyroidism):** ë‚®ì€ ê°‘ìƒì„  í˜¸ë¥´ëª¬ â†’ ì‹œìƒí•˜ë¶€ê°€ TRH ë¶„ë¹„ â†’ TRHê°€ TSHë¿ë§Œ ì•„ë‹ˆë¼ **Prolactin ë¶„ë¹„ë„ ìê·¹**. (ì´ ê²½ìš° ê°‘ìƒì„ ì„ ì¹˜ë£Œí•´ì•¼ í•¨)\n- **Diagnosis & Threshold:**\n    - **> 200 ng/mL:** ì´ ìˆ˜ì¹˜ëŠ” ê±°ì˜ í™•ì‹¤í•˜ê²Œ **Prolactinoma(ì¢…ì–‘)**ì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì•½ê°„ ìƒìŠ¹í•œ ìˆ˜ì¹˜ëŠ” ë‹¤ë¥¸ ì›ì¸ì¼ ìˆ˜ ìˆìŒ.\n- **Management Dilemma: Surgery vs. Meds ğŸ’Š**\n    - **Microprolactinoma (<10mm, ë¬´ì¦ìƒ):** **Just Watch it.** (ì¹˜ë£Œ ë¶ˆí•„ìš”).\n    - **Macroprolactinoma (>10mm) ë˜ëŠ” ì¦ìƒ(ìœ ì¦™ë¶„ë¹„, ì‹œì•¼ê²°ì†)ì´ ìˆëŠ” ê²½ìš°:**\n        - **1ì°¨ ì¹˜ë£Œ:** â˜… **Medical Management (Dopamine Agonists)**\n        - **ì•½ë¬¼ ì„ íƒ:** **Cabergoline** (ì„ í˜¸ë¨, ë¶€ì‘ìš© ì ìŒ) > Bromocriptine.\n        - **â˜… Counter-intuitive Point:** í™˜ìê°€ ì¢…ì–‘ìœ¼ë¡œ ì¸í•´ **ì‹œì•¼ ê²°ì†(Vision loss)**ì´ ìˆì–´ë„ ìˆ˜ìˆ ì´ ì•„ë‹Œ **ì•½ë¬¼(Cabergoline)**ì´ ìš°ì„ ì…ë‹ˆë‹¤. ì•½ë¬¼ì´ ì¢…ì–‘ì„ ë§¤ìš° ë¹ ë¥´ê²Œ ì¤„ì—¬ì¤ë‹ˆë‹¤. ìˆ˜ìˆ ì€ ì•½ë¬¼ ì‹¤íŒ¨ ì‹œì˜ 'Back-up plan'ì…ë‹ˆë‹¤.\n### B. Water Balance: SIADH vs. Diabetes Insipidus (DI) âš–ï¸\n\"Wet vs. Dry\" ì‹¸ì›€ì…ë‹ˆë‹¤.\n### 1. Diabetes Insipidus (DI) - \"Dry\" & High Sodium\n- **ì¹˜ë£Œ:** Desmopressin (í˜¸ë¥´ëª¬ ëŒ€ì²´).\n- **â˜… The Potential Pitfall (í™˜ì ë’¤ì§‘ê¸° ìœ„í—˜):**\n    - í™˜ìì˜ ê°ˆì¦ ê¸°ì „(Thirst mechanism)ì€ ê³¼ë„í•˜ê²Œ ì‘ë™ ì¤‘(Overdrive)ì´ë¼ ë¬¼ì„ ê³„ì† ë§ˆì‹­ë‹ˆë‹¤.\n    - ì´ë•Œ Desmopressin(ê°•ë ¥í•œ ì†Œë³€ ì–µì œ ì‹ í˜¸)ì„ íˆ¬ì—¬í•˜ë©´ ì†Œë³€ ë°°ì¶œì€ ë©ˆì¶”ì§€ë§Œ, í™˜ìê°€ ë¬¼ ë§ˆì‹œê¸°ë¥¼ ë©ˆì¶”ì§€ ì•Šì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n    - **ê²°ê³¼:** ê¸‰ê²©í•œ í˜ˆì•¡ í¬ì„(Dilution) â†’ **Iatrogenic SIADH** (ì˜ì›ì„± SIADH) â†’ ì‹¬ê°í•œ ì €ë‚˜íŠ¸ë¥¨í˜ˆì¦(Hyponatremia).\n    - **êµí›ˆ:** ì•½ ì²˜ë°© í›„ ë°˜ì‘ì„ ëª¨ë‹ˆí„°ë§í•´ì•¼ í•¨.\n### 2. SIADH - \"Wet\" & Low Sodium\n- **ì¼ë°˜ì  ì¹˜ë£Œ:** ìˆ˜ë¶„ ì œí•œ(Fluid restriction).\n- **â˜… Red Alert Scenario (ì‘ê¸‰):**\n    - í™˜ìê°€ ì €ë‚˜íŠ¸ë¥¨í˜ˆì¦ìœ¼ë¡œ ì¸í•´ **ë°œì‘(Seizures)ì´ë‚˜ í˜¼ìˆ˜(Coma)** ìƒíƒœì¸ ê²½ìš°.\n    - **ì¹˜ë£Œ:** **Hypertonic Saline (3%)**. (ìœ ë¦¬ì°½ì„ ê¹¨ê³  ì ê·¹ì ìœ¼ë¡œ ê°œì…í•´ì•¼ í•  ë•Œ)\n---\n## 3. The Thyroid: A Beast of a Topic ğŸ¦‹\n### A. Graves' Disease (Hyperthyroidism) ğŸ”¥\nì¹˜ë£Œë²•ì€ í™˜ìê°€ ëˆ„êµ¬ëƒì— ë”°ë¼ ë‹¬ë¼ì§‘ë‹ˆë‹¤. (Meds vs. RAI vs. Surgery)\n### 1. Drugs (Antithyroid Drugs)\nì„ì‹  ì—¬ë¶€ì— ë”°ë¥¸ **\"Pregnancy Switch\"** ê·œì¹™ì´ ì¤‘ìš”í•©ë‹ˆë‹¤.\n| ì‹œê¸° | ì•½ë¬¼ ì„ íƒ | ì´ìœ  (â˜… Side Effects) |\n| --- | --- | --- |\n| **ì„ì‹  1ë¶„ê¸° (1st Trimester)** | **PTU** (Propylthiouracil) | Methimazoleì€ ê¸°í˜•(**Aplasia Cutis**: ë‘í”¼ ê²°ì† ë“±) ìœ ë°œ ìœ„í—˜. |\n| **ì„ì‹  2, 3ë¶„ê¸°** | **Methimazole** | PTUëŠ” **ê°„ ë…ì„±(Hepatotoxicity)** ìœ„í—˜ì´ ìˆì–´, ê¸°ê´€ í˜•ì„±(Organogenesis)ì´ ëë‚œ í›„ì—ëŠ” ê°„ ë³´í˜¸ë¥¼ ìœ„í•´ êµì²´. |\n### 2. Radioactive Iodine (RAI) â˜¢ï¸\n- ëŒ€ë¶€ë¶„ì˜ í™˜ìë¥¼ ì˜êµ¬ì ì¸ ê°‘ìƒì„ ê¸°ëŠ¥ì €í•˜ì¦ìœ¼ë¡œ ë§Œë“¦ (í‰ìƒ ì•½ ë³µìš© í•„ìš”).\n- **â˜… Absolute Contraindication:** **Graves' Ophthalmopathy** (ëˆˆ íŠ€ì–´ë‚˜ì˜´).\n    - RAIëŠ” ê¸‰ì„± ì—¼ì¦ì„ ìœ ë°œí•˜ì—¬ ëˆˆ ì§ˆí™˜ì„ í›¨ì”¬ ì•…í™”ì‹œí‚¬ ìˆ˜ ìˆìŒ.\n    - ëˆˆ ì¦ìƒì´ ì‹¬í•˜ë©´ **ìˆ˜ìˆ (Surgery) ë˜ëŠ” ì•½ë¬¼**ë¡œ ê°€ì•¼ í•¨.\n### 3. Monitoring (Mechanism Question) ğŸ“‰","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-181","focus_area":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"- ì¹˜ë£Œ í›„ í™˜ìê°€ ì¢‹ì•„ì ¸ë„ **TSHë¥¼ ë°”ë¡œ ì²´í¬í•˜ì§€ ë§ ê²ƒ.**\n- **ì´ìœ :** ë‡Œí•˜ìˆ˜ì²´ê°€ ì˜¤ë«ë™ì•ˆ ì–µì œë˜ì–´ ìˆì—ˆê¸° ë•Œë¬¸ì—(Sluggish), ìˆ˜ê°œì›”ê°„ ê¹¨ì–´ë‚˜ì§€ ì•Šì„ ìˆ˜ ìˆìŒ. TSHëŠ” ì—¬ì „íˆ ë‚®ê²Œ ë‚˜ì˜´.\n- **ì •ë‹µ:** **Free T4 & Total T3**ë¥¼ í™•ì¸í•˜ì—¬ ê³¼ë‹¤ íˆ¬ì—¬(Overdosing)ë¥¼ ë°©ì§€í•´ì•¼ í•¨.\n### B. Hypothyroidism (Low Thyroid) â„ï¸\nStandard ì¹˜ë£ŒëŠ” Levothyroxineì´ì§€ë§Œ, ë‘ ê·¸ë£¹ì—ì„œ ê·œì¹™ì´ ë°”ë€ë‹ˆë‹¤.\n### 1. The Elderly (ë…¸ì¸ í™˜ì) ğŸ‘´\n- **Mantra:** **\"Start low and go slow.\"** (25~50 mcg).\n- **ì´ìœ :** ê°‘ìƒì„  í˜¸ë¥´ëª¬ì€ ì‹¬ê·¼ ì‚°ì†Œ ìš”êµ¬ëŸ‰ì„ ì¦ê°€ì‹œí‚µë‹ˆë‹¤(Revs up the heart engine). ê´€ìƒë™ë§¥ ì§ˆí™˜ì´ ìˆëŠ” ë…¸ì¸ì—ê²Œ ê³ ìš©ëŸ‰ì„ ì£¼ë©´ **í˜‘ì‹¬ì¦(Angina), ë¶€ì •ë§¥, ì‹¬ì¥ë§ˆë¹„**ë¥¼ ìœ ë°œí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n### 2. Pregnancy (ì„ì‹ ë¶€) ğŸ¤°\n- **Action:** ì„ì‹  í…ŒìŠ¤íŠ¸ ì–‘ì„± ì¦‰ì‹œ **ìš©ëŸ‰ì„ ì¦ëŸ‰(ì•½ 30%)**í•´ì•¼ í•¨. (TSH ê²°ê³¼ ê¸°ë‹¤ë¦¬ì§€ ë§ê³  ì¦‰ì‹œ)\n- **â˜… Mechanism (The Sponge Effect):**\n    - ì„ì‹  ì¤‘ ë†’ì€ ì—ìŠ¤íŠ¸ë¡œê² â†’ ê°„ì—ì„œ **TBG (Thyroxine Binding Globulin)** ìƒì„± ì¦ê°€.\n    - TBGê°€ í˜ˆì¤‘ Free T4ë¥¼ ìŠ¤í€ì§€ì²˜ëŸ¼ ë¹¨ì•„ë“¤ì„ â†’ í™œì„± í˜¸ë¥´ëª¬ ë¶€ì¡±.\n    - íƒœì•„ì˜ ë‡Œ ë°œë‹¬ì€ 1ë¶„ê¸°ì— ëª¨ì²´ ê°‘ìƒì„  í˜¸ë¥´ëª¬ì— ì „ì ìœ¼ë¡œ ì˜ì¡´í•˜ë¯€ë¡œ ì¦‰ê°ì ì¸ ì¦ëŸ‰ì´ í•„ìˆ˜.\n---\n## 4. The Adrenals: Stress & Pressure âš¡\n### A. Hyperaldosteronism (Conn Syndrome)\n- ì¦ìƒ: ê³ í˜ˆì•• + ì €ì¹¼ë¥¨í˜ˆì¦.\n- **Management depends on counts:**\n    - **Unilateral (í•œìª½):** Adenoma â†’ **Surgery** (Cut it out).\n    - **Bilateral (ì–‘ìª½):** Hyperplasia â†’ **Medical Mgmt** (Spironolactone, Eplerenone).\n    - **â˜… Why not remove both?** ì–‘ìª½ ë¶€ì‹ ì„ ì œê±°í•˜ë©´ í™˜ìë¥¼ **Addison's Disease**(ë¶€ì‹ ë¶€ì „)ë¡œ ë§Œë“¤ê²Œ ë¨. í‰ìƒ ìŠ¤í…Œë¡œì´ë“œ ì˜ì¡´ ë° Adrenal Crisis ìœ„í—˜ì— ë¹ ëœ¨ë¦¬ëŠ” ê²ƒì€ í˜ˆì•• ì¡°ì ˆì„ ìœ„í•´ ë„ˆë¬´ í° ëŒ€ê°€ì„.\n### B. Adrenal Crisis & Septic Shock ğŸš¨\n- ì €í˜ˆì••, ì‡¼í¬ ìƒí™©. ìˆ˜ì•¡ê³¼ Hydrocortisone íˆ¬ì—¬.\n- **â˜… Pharmacology Pearl (Anesthetic Risk):**\n    - **í”¼í•´ì•¼ í•  ì•½ë¬¼:** **Etomidate**.\n    - **ì´ìœ :** EtomidateëŠ” ì‹¬ì¥ì—ëŠ” ì•ˆì •ì ì´ì§€ë§Œ, **11-beta-hydroxylase**ë¥¼ ì–µì œí•¨ (ì½”ë¥´í‹°ì†” ìƒì„±ì˜ ë§ˆì§€ë§‰ ê´€ë¬¸).\n    - ì´ë¯¸ ìŠ¤íŠ¸ë ˆìŠ¤ ìƒí™©ì¸ íŒ¨í˜ˆì¦ í™˜ìì—ê²Œ Etomidateë¥¼ ì“°ë©´ ì½”ë¥´í‹°ì†” ìƒì„±ì„ ë§‰ì•„ **ì˜ì›ì„± ë¶€ì‹  ìœ„ê¸°(Iatrogenic Adrenal Crisis)**ë¥¼ ìœ ë°œí•˜ì—¬ í™˜ìë¥¼ ë²¼ë‘ ëìœ¼ë¡œ ë°€ ìˆ˜ ìˆìŒ.\n    - **ëŒ€ì•ˆ:** Ketamine ë“± ì‚¬ìš©.\n---\n## 5. The Parathyroid & Calcium ğŸ¦´\n### A. Tertiary Hyperparathyroidism\n- **ë§¥ë½:** ë§Œì„± ì‹ ë¶€ì „(Renal Failure).\n- **ê¸°ì „:** ì˜¤ë«ë™ì•ˆ ì €ì¹¼ìŠ˜í˜ˆì¦ì— ëŒ€ì‘í•˜ë‹¤ê°€ ë¶€ê°‘ìƒì„ ë“¤ì´ **ììœ¨ì„±(Autonomous)**ì„ ê°–ê²Œ ë¨(Go rogue). ì¹¼ìŠ˜ ìˆ˜ì¹˜ê°€ êµì •ë˜ê±°ë‚˜ ì‹ ì¥ ì´ì‹ì„ í•´ë„ ìŠ¤ìœ„ì¹˜ê°€ êº¼ì§€ì§€ ì•ŠìŒ.\n- **ê²°ê³¼:** High Calcium + High PTH. â†’ **ìˆ˜ìˆ  í•„ìš”.**\n### B. Calciphylaxis & Basal Ganglia Calcification\n- **ìœ„í—˜:** Calcium x Phosphorus ê³±(Product)ì´ **55**ë¥¼ ë„˜ìœ¼ë©´ í˜ˆì•¡ì´ ê³¼í¬í™”(Supersaturated)ë¨. ë¯¸ë„¤ë„ì´ ê³ ì²´í™”(Solid rock)ë˜ì–´ ì¹¨ì „ë¨.\n- **ì¦ìƒ:** í”¼ë¶€ ê¶¤ì–‘(Ulcers) ë¿ë§Œ ì•„ë‹ˆë¼ **ë‡Œ(Basal Ganglia) ì„íšŒí™”** ê°€ëŠ¥.\n- **ê²°ê³¼:** íŒŒí‚¨ìŠ¨ë³‘ê³¼ ìœ ì‚¬í•œ ì¶”ì²´ì™¸ë¡œ ì¦ìƒ(Extrapyramidal symptoms), ë–¨ë¦¼(Tremors) ìœ ë°œ ê°€ëŠ¥.\n---","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-201","focus_area":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","tags":["usmle-step2","core","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"## 6. Diabetes Maintenance: Prevention ğŸ›¡ï¸\n### A. Neuropathy Screening ğŸ¦¶\n- **Monofilament Test:** ì •í™•íˆ **10gì˜ ì••ë ¥**ì„ ê°€í•¨.\n- **ëª©ì :** **Large nerve fibers** (ë³´í˜¸ ê°ê°)ì˜ ì†ì‹¤ì„ í…ŒìŠ¤íŠ¸.\n- í™˜ìê°€ ì´ ì••ë ¥ì„ ëª» ëŠë¼ë©´ ì‹ ë°œ ì† ìê°ˆì´ë‚˜ ë¬¼ì§‘ì„ ëŠë¼ì§€ ëª»í•´ ê¶¤ì–‘(Ulcer) â†’ ê°ì—¼ â†’ ì ˆë‹¨(Amputation)ìœ¼ë¡œ ì´ì–´ì§. \"Low tech test with high stakes implications.\"\n### B. Elderly A1C Goals ğŸ¯\n- **ëª©í‘œ:** **< 8%** (ì¼ë°˜ì ì¸ < 7% ë³´ë‹¤ ì™„í™”).\n- **â˜… Why?** ë…¸ì¸ì—ê²ŒëŠ” ê³ í˜ˆë‹¹ë³´ë‹¤ **ì €í˜ˆë‹¹(Hypoglycemia)**ì´ í›¨ì”¬ ì¹˜ëª…ì ì„.\n    - 30ì„¸ì˜ ì €í˜ˆë‹¹ = ì†ë–¨ë¦¼, ë°°ê³ í””.\n    - 80ì„¸ì˜ ì €í˜ˆë‹¹ = ì–´ì§€ëŸ¬ì›€, ë‚™ìƒ(Fall), **ê³ ê´€ì ˆ ê³¨ì ˆ(Hip fracture)** â†’ ì‚¬ë§ë¥  ê¸‰ì¦.\n    - ì—„ê²©í•œ ì¡°ì ˆ(Tight control)ì˜ ì´ë“ë³´ë‹¤ ë‚™ìƒì˜ ìœ„í—˜ì´ ë” í¼.\n---\n## 7. Rapid Fire Scenarios (Stress Test) ğŸ”¥ğŸƒâ€â™‚ï¸\nê°•ì˜ ë§ˆì§€ë§‰ì— ì§„í–‰ëœ ì‹¤ì œ ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤ ìš”ì•½ì…ë‹ˆë‹¤.\n1. **Prolactinoma (12mm) + Vision Loss:**\n    - ìˆ˜ìˆ ? **NO.**\n    - **ì •ë‹µ:** **Cabergoline** (Meds first). ì•½ë¬¼ì´ ì¢…ì–‘ì„ ë¹ ë¥´ê²Œ ì¤„ì„.\n2. **Graves' Disease + Bulging Eyes (Exophthalmos):**\n    - Radioactive Iodine? **Absolutely NOT.**\n    - **ì •ë‹µ:** **Surgery** (Thyroidectomy) ë˜ëŠ” Meds. ë°©ì‚¬ì„ ì€ ëˆˆì„ ì•…í™”ì‹œí‚´.\n3. **Graves' Disease + Pregnancy (8 weeks/1st Trimester):**\n    - Methimazole? **NO.**\n    - **ì •ë‹µ:** **PTU**ë¡œ ë³€ê²½ (íƒœì•„ ê¸°í˜• ë°©ì§€). *Note: 2ë¶„ê¸°ì— Methimazoleë¡œ ë‹¤ì‹œ ë³€ê²½(ê°„ ë³´í˜¸).*\n4. **Hypothyroidism + Positive Pregnancy Test:**\n    - ë‹¤ìŒ ì˜ˆì•½ ê¸°ë‹¤ë¦¬ê¸°? **NO.**\n    - **ì •ë‹µ:** ì¦‰ì‹œ Levothyroxine ìš©ëŸ‰ **30% ì¦ëŸ‰** (2 pills extra/week). TBG Sponge effect í¬í™”ì‹œí‚¤ê¸° ìœ„í•´.\n5. **Septic Shock + Intubation Need:**\n    - Etomidate? **Avoid it.**\n    - **ì •ë‹µ:** Ketamine ì‚¬ìš©. (EtomidateëŠ” ì½”ë¥´í‹°ì†” ì°¨ë‹¨ ìœ„í—˜).\n6. **SIADH + Seizures (Hyponatremia):**\n    - Fluid Restriction? **Not enough.**\n    - **ì •ë‹µ:** **3% Hypertonic Saline.** (ì‘ê¸‰ ìƒí™©).\n7. **85ì„¸ ë‹¹ë‡¨ í™˜ì + A1C 7.8%:**\n    - ì¸ìŠë¦° ì¦ëŸ‰? **NO.**\n    - **ì •ë‹µ:** **Leave it alone.** (ëª©í‘œëŠ” < 8%). ì €í˜ˆë‹¹ìœ¼ë¡œ ì¸í•œ ë‚™ìƒ ìœ„í—˜ì´ ë” í¼.\n---\n**Closing Thought:** ë‚´ë¶„ë¹„í•™ì€ ë‹¨ìˆœíˆ ì•½ì´ ë¬´ì—‡ì¸ì§€(What)ê°€ ì•„ë‹ˆë¼, **í™˜ìê°€ ëˆ„êµ¬ì¸ì§€(Who)**ì— ë”°ë¼ ê· í˜•ì„ ë§ì¶”ëŠ” í•™ë¬¸ì…ë‹ˆë‹¤. \"Respect the balance.\"\n# USMLE Step 2 ëŒ€ë¹„: ê°‘ìƒì„  ì§ˆí™˜ ì‹¬ì¸µ ë¶„ì„ (Thyroid Deep Dive)\n---\n## 1. Introduction: Step 1ê³¼ Step 2ì˜ ì°¨ì´ì \n- **ê°‘ìƒì„ ì˜ ì¤‘ìš”ì„±:** ëª© ì¤‘ì•™ì— ìœ„ì¹˜í•œ ë‚˜ë¹„ ëª¨ì–‘ì˜ ê¸°ê´€ìœ¼ë¡œ, ì¡´ì¬ì˜ ì†ë„ë¥¼ ê²°ì •í•˜ëŠ” ê°•ë ¥í•œ ê¸°ê´€ì…ë‹ˆë‹¤. ë‚´ê³¼ ì˜ì—­ì—ì„œ ê°€ì¥ **High Yield** ì£¼ì œ ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤.\n- **ì ‘ê·¼ ë°©ì‹ì˜ ë³€í™”:**\n    - Step 1: ë¶„ì ìƒë¬¼í•™, ì¡°ì§í•™, í¬ê·€ ì•” ë“±ì— ì§‘ì¤‘í•©ë‹ˆë‹¤.\n    - Step 2: **ê´€ë¦¬(Management)**ì™€ **ë‹¤ìŒ ë‹¨ê³„(Next Best Step)**ê°€ í•µì‹¬ì…ë‹ˆë‹¤.\n    - ì„ìƒì  ì˜ì‚¬ê²°ì •: ë‹¨ìˆœíˆ ì§ˆë³‘ì´ ë¬´ì—‡ì¸ì§€ ì•„ëŠ” ê²ƒì„ ë„˜ì–´, \"TSHê°€ ë‚®ê³  ê²°ì ˆì´ ë§Œì ¸ì§ˆ ë•Œ, ì¡°ì§ê²€ì‚¬ë¥¼ í•  ê²ƒì¸ê°€ ìŠ¤ìº”ì„ í•  ê²ƒì¸ê°€?\"ë¥¼ ê²°ì •í•˜ëŠ” ê²ƒì´ ì ìˆ˜ë¥¼ ê°€ë¦…ë‹ˆë‹¤.\n- **ê°•ì˜ ë¡œë“œë§µ:**\n    1. ê°‘ìƒì„  í•­ì§„ì¦ (Hyperthyroidism) ë° ì§„ë‹¨ ì•Œê³ ë¦¬ì¦˜\n    2. ê°‘ìƒì„  ì €í•˜ì¦ (Hypothyroidism) ë° í•˜ì‹œëª¨í†  (Hashimoto's)\n    3. ì„ì‹  ì¤‘ ê°‘ìƒì„  ì§ˆí™˜ (ê³ ìœ„í—˜êµ°, ìƒë¦¬í•™ì  ë³€í™”)\n    4. íšŒìƒ‰ ì§€ëŒ€ (Subclinical, Nodule, Euthyroid Sick Syndrome)\n---\n## 2. ê°‘ìƒì„  í•­ì§„ì¦ (Hyperthyroidism) í”„ë ˆì„ì›Œí¬ ğŸŒ¡ï¸\n### 2.1 ì¦ìƒê³¼ ë³‘íƒœìƒë¦¬\n- **í™˜ì ë¬˜ì‚¬ (Vignette):** êµê°ì‹ ê²½ ê³¼í•­ì§„ ìƒíƒœ (Sympathetic Overdrive).\n    - **ë”ìœ„ ë¶ˆë‚´ì„±:** í•œê²¨ìš¸ì— ì°½ë¬¸ì„ ì—¬ëŠ” ì‚¬ëŒ. ë‚¨ë“¤ì€ ì¶”ì›Œí•˜ëŠ”ë° í˜¼ì ë•€ì„ í˜ë¦¼.\n    - **ì²´ì¤‘ ê°ì†Œ:** ì‹ìš•ì€ ì •ìƒì´ê±°ë‚˜ ì¦ê°€í–ˆëŠ”ë°ë„ ì‚´ì´ ë¹ ì§ (ëŒ€ì‚¬ ìš©ê´‘ë¡œê°€ ë„ˆë¬´ ëœ¨ê±°ì›€). â˜…\n    - **ê¸°íƒ€:** ì‹¬ê³„í•­ì§„(Palpitations), ë¯¸ì„¸ ì§„ì „(Tremor), ì„¤ì‚¬/ë¹ˆë²ˆí•œ ë°°ë³€(ì¥ ìš´ë™ í•­ì§„).","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-221","focus_area":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","tags":["usmle-step2","core","treatment","pathophysiology"]}
